<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006744</article-id><article-id pub-id-type="pmc">PMC11861054</article-id><article-id pub-id-type="doi">10.3390/vaccines13020198</article-id><article-id pub-id-type="publisher-id">vaccines-13-00198</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Achievement and Challenges in Orthohantavirus Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chai</surname><given-names>Shiqi</given-names></name><xref rid="af1-vaccines-13-00198" ref-type="aff">1</xref><xref rid="fn1-vaccines-13-00198" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1352-6461</contrib-id><name><surname>Wang</surname><given-names>Limei</given-names></name><xref rid="af2-vaccines-13-00198" ref-type="aff">2</xref><xref rid="fn1-vaccines-13-00198" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Hong</given-names></name><xref rid="af1-vaccines-13-00198" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00198" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2075-3272</contrib-id><name><surname>Jiang</surname><given-names>Hong</given-names></name><xref rid="af1-vaccines-13-00198" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00198" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-13-00198"><label>1</label>Center for Diagnosis and Treatment of Infectious Diseases, TangDu Hospital, The Fourth Military Medical University, Xi&#x02019;an 710038, China; <email>18820134730@163.com</email></aff><aff id="af2-vaccines-13-00198"><label>2</label>Department of Microbiology and Pathogenic Biology, School of Basic Medicine, The Fourth Military Medical University, Xi&#x02019;an 710032, China; <email>wanglim@fmmu.edu.cn</email></aff><author-notes><corresp id="c1-vaccines-13-00198"><label>*</label>Correspondence: <email>jiangh518@126.com</email> (H.J.); <email>duhong811118@163.com</email> (H.D.); Tel.: +86-29-84778847 (H.J.)</corresp><fn id="fn1-vaccines-13-00198"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>198</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>08</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Orthohantaviruses (also known as hantaviruses) are pathogens that cause two distinct, yet related forms of severe human disease: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). These diseases pose a significant threat to global public health due to their high case fatality rates, which can range from 1% to 50%. In recent years, an increasing number of countries and regions have reported human cases, underscoring the urgent need for improved understanding, prevention, and treatment strategies. Given the severity of these diseases and the lack of specific post-exposure antiviral treatments, preventive measures are critical. For several decades, substantial efforts have been dedicated to developing orthohantavirus vaccines, leading to significant advancements. The first large-scale deployment involved inactivated vaccines, which played a crucial role in reducing HFRS incidence in South Korea and China. Subunit vaccines, viral vector vaccines, and virus-like particle (VLP) vaccines have also been extensively researched. Nucleic acid vaccines, including both mRNA and DNA vaccines, hold the greatest potential for future development due to their rapid design and production cycles, ability to elicit robust immune responses, ease of storage and transportation, and adaptable production platforms. Ongoing advancements in computer technology and artificial intelligence promise to further enhance the development of more effective orthohantavirus vaccines.</p></abstract><kwd-group><kwd>vaccine</kwd><kwd>orthohantavirus</kwd><kwd>hemorrhagic fever with renal syndrome</kwd><kwd>hantavirus pulmonary syndrome</kwd></kwd-group><funding-group><award-group><funding-source>Discipline Innovation and Development Program of TangDu Hospital, Fourth Military Medical University</funding-source><award-id>2021LCYJ025</award-id></award-group><award-group><funding-source>Discipline Boosting Program Project of TangDu Hospital, Fourth Military Medical University</funding-source><award-id>2024JSYX010</award-id></award-group><funding-statement>This work was funded by the Discipline Innovation and Development Program of TangDu Hospital, Fourth Military Medical University (2021LCYJ025). This work was also funded by the Discipline Boosting Program Project of TangDu Hospital, Fourth Military Medical University (2024JSYX010).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00198"><title>1. Introduction</title><p>The <italic toggle="yes">Orthohantavirus</italic> genus belongs to the <italic toggle="yes">Hantaviridae</italic> family within the <italic toggle="yes">Elliovirales</italic> order, and has been recognized as comprising over 35 distinct species [<xref rid="B1-vaccines-13-00198" ref-type="bibr">1</xref>]. These species have a documented presence across the world, except for Antarctica [<xref rid="B2-vaccines-13-00198" ref-type="bibr">2</xref>]. Orthohantaviruses primarily cause two fatal human diseases, hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) [<xref rid="B3-vaccines-13-00198" ref-type="bibr">3</xref>]. HFRS accounts for more than 20,000 cases annually in Asia and Europe, with an associated case fatality rate ranging from 0.1% to 15% [<xref rid="B4-vaccines-13-00198" ref-type="bibr">4</xref>]. In contrast, HPS is found exclusively in South America and North America, but it poses a significantly higher case fatality rate of up to 50% [<xref rid="B5-vaccines-13-00198" ref-type="bibr">5</xref>]. The majority of HPS patients succumb within 1 to 2 days after hospital admission [<xref rid="B6-vaccines-13-00198" ref-type="bibr">6</xref>]. Therefore, orthohantaviruses poses a significant global public health challenge [<xref rid="B4-vaccines-13-00198" ref-type="bibr">4</xref>].</p><p>Reservoir hosts of orthohantaviruses are widely distributed in nature, presenting a challenge for eradication efforts [<xref rid="B4-vaccines-13-00198" ref-type="bibr">4</xref>]. Orthohantaviruses have been known to be transmitted among various murid and cricetid rodent species in both the Eastern and Western hemispheres, with <italic toggle="yes">Apodemus</italic>, <italic toggle="yes">Clethrionomys</italic>, and <italic toggle="yes">Rattus</italic> serving as primary reservoir hosts [<xref rid="B2-vaccines-13-00198" ref-type="bibr">2</xref>,<xref rid="B7-vaccines-13-00198" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00198" ref-type="bibr">8</xref>]. As different kinds of orthohantaviruses may share one host, the virus&#x02013;host species specificity paradigm could be blurred and thus contribute to the virus&#x02019;s spread and likely to the evolution of closely related pathogens. Orthohantaviruses are typically transmitted to humans via urine, feces, saliva, and aerosols generated by reservoir hosts; however, transmission through animal bites is infrequent [<xref rid="B9-vaccines-13-00198" ref-type="bibr">9</xref>]. Human-to-human transmission of Andes virus (ANDV) has been documented [<xref rid="B10-vaccines-13-00198" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00198" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00198" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00198" ref-type="bibr">13</xref>], although this mode of transmission lacks widespread consensus [<xref rid="B14-vaccines-13-00198" ref-type="bibr">14</xref>].</p><p>The pathogenic mechanism underlying orthohantavirus infection remains incompletely understood, and there are currently no specific antiviral treatments. Therefore, the development of more effective vaccines is crucial for both prevention and control strategies against orthohantavirus infection. In recent decades, various vaccine approaches have been investigated, including attenuated vaccines, inactivated vaccines, virus-like particles, recombinant proteins, and gene vaccines. Currently, no orthohantavirus vaccine has received approval from the WHO [<xref rid="B15-vaccines-13-00198" ref-type="bibr">15</xref>]. However, scientists in China, South Korea, the United States, Russia, and other countries have conducted extensive research on vaccine development, efficacy, and safety. Notably, several vaccines developed in China and South Korea have been in use within these countries for many years. We present a comprehensive overview of the progress made in orthohantavirus vaccine research, as well as the benefits, drawbacks, and challenges associated with different types of vaccines.</p><sec id="sec1dot1-vaccines-13-00198"><title>1.1. The Growing Demand for Vaccines Against Orthohantaviruses</title><p>Hemorrhagic fever conditions have been clinically presented since the <italic toggle="yes">Yellow Emperor&#x02019;s Internal Canon</italic> in imperial China during the Warring States period (475&#x02013;221 BCE) [<xref rid="B16-vaccines-13-00198" ref-type="bibr">16</xref>], and were then noted during World War 1 in Asian and European countries [<xref rid="B2-vaccines-13-00198" ref-type="bibr">2</xref>,<xref rid="B17-vaccines-13-00198" ref-type="bibr">17</xref>]. More scientifically accurate records of the disease have been available since approximately 1913 in Russia [<xref rid="B2-vaccines-13-00198" ref-type="bibr">2</xref>]. During the Korean War in 1951, hundreds of U.S. military personnel were diagnosed with &#x0201c;Korean hemorrhagic fever,&#x0201d; also called &#x0201c;epidemic hemorrhagic fever,&#x0201d; causing international concern [<xref rid="B18-vaccines-13-00198" ref-type="bibr">18</xref>]. Since then, numerous analogous cases have emerged globally, and the disease was subsequently assigned the standardized name HFRS by the World Health Organization (WHO) in 1982 [<xref rid="B2-vaccines-13-00198" ref-type="bibr">2</xref>]. Currently, nephropathia epidemica (NE), a mild form of HFRS, remains a prevalent zoonosis in Russia [<xref rid="B19-vaccines-13-00198" ref-type="bibr">19</xref>] and Finland [<xref rid="B20-vaccines-13-00198" ref-type="bibr">20</xref>]. The first cases of HPS were recognized in the U.S. in 1993 [<xref rid="B21-vaccines-13-00198" ref-type="bibr">21</xref>], and since that time, the syndrome has been recognized in a number of other Western Hemisphere countries (<xref rid="vaccines-13-00198-f001" ref-type="fig">Figure 1</xref>).</p><p>Recent decades have seen increased likelihood of contact with orthohantavirus-infected wildlife, primarily rodents, due to human encroachment on their habitats coupled with climate change and landscape modifications [<xref rid="B67-vaccines-13-00198" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-13-00198" ref-type="bibr">68</xref>]. The resurgence of global HFRS outbreaks in 2017 has refocused attention on this long-standing public health issue. Additionally, ongoing global conflicts may expose more individuals, including soldiers, to orthohantaviruses. As climate change and deforestation drive rodent population growth, the incidence of human orthohantavirus infections is expected to rise, transcending previous geographical limitations [<xref rid="B69-vaccines-13-00198" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-13-00198" ref-type="bibr">70</xref>]. Consequently, preventing and managing orthohantavirus infections has become imperative. Projections indicate a growing global demand for orthohantavirus vaccines [<xref rid="B71-vaccines-13-00198" ref-type="bibr">71</xref>]. Given the heightened risk of outbreaks and the high mortality rates associated with both HFRS and HPS, there is an urgent need to strengthen medical preparedness for orthohantavirus infections.</p></sec><sec id="sec1dot2-vaccines-13-00198"><title>1.2. The Immunological Basis for Rational Vaccine Design</title><p>Orthohantavirus is an enveloped virus with a tri-segment negative-sense RNA genome [<xref rid="B72-vaccines-13-00198" ref-type="bibr">72</xref>]. The virus particle is oval or spherical, measuring 80&#x02013;120 nm in diameter. The RNA segments of the orthohantavirus genome are designated as small (S, 1.8&#x02013;2.1 kb), medium (M, 3.7&#x02013;3.8 kb), and large (L, 6.5&#x02013;6.6 kb). The conserved 3&#x02019;- and 5&#x02019;-ends of the segments may form a panhandle structure to act as the viral promoter [<xref rid="B73-vaccines-13-00198" ref-type="bibr">73</xref>]. The S and M segments encode the nucleocapsid protein (NP) and the envelope glycoprotein (GP, a polyprotein of 1133&#x02013;1158 aa residues composed of Gn and Gc), respectively. The L segment encodes the RNA-dependent RNA polymerase (RdRp) [<xref rid="B74-vaccines-13-00198" ref-type="bibr">74</xref>]. Each virus particle usually comprises equivalent quantities of genomic RNA, featuring a solitary viral RdRp molecule bound to each RNA segment. These RNA segments are encapsulated by NP proteins, thereby constituting ribonucleoprotein complexes. The RdRp is responsible for both the transcription and replication processes of the virus [<xref rid="B75-vaccines-13-00198" ref-type="bibr">75</xref>]. RNA polymerase cleaves cellular mRNA, forming capped primers, which are protected from degradation by bounding viral NP. NP consists of approximately 433 amino acid residues (about 50 kDa in size) with high conservatism. GP may interact with host cellular surface proteins, facilitating cellular entry [<xref rid="B75-vaccines-13-00198" ref-type="bibr">75</xref>]. As mentioned earlier, orthohantavirus has the capacity for reassortment. Notably, the resultant reassorted viruses consistently preserved the S and L segments from one parental orthohantavirus, whereas the M segment was acquired from the alternative parent [<xref rid="B76-vaccines-13-00198" ref-type="bibr">76</xref>] (<xref rid="vaccines-13-00198-f002" ref-type="fig">Figure 2</xref>).</p><p>GPs play critical roles in initiating humoral immunity and can stimulate the production of virus-specific neutralizing antibodies [<xref rid="B77-vaccines-13-00198" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-13-00198" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-13-00198" ref-type="bibr">79</xref>]. Monoclonal antibodies targeting GPs have demonstrated virus-neutralizing activity, both in vitro and in vivo [<xref rid="B80-vaccines-13-00198" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-13-00198" ref-type="bibr">81</xref>]. However, GPs have weak immunogenicity, characterized by a delayed antibody response and low antibody titers [<xref rid="B82-vaccines-13-00198" ref-type="bibr">82</xref>]. Among GPs, the Gc glycoprotein is responsible for directing viral fusion activity and is classified as a class II viral fusion protein [<xref rid="B83-vaccines-13-00198" ref-type="bibr">83</xref>]. Antibodies against Gc can prevent viral entry into the host.</p><p>In contrast to GPs, NP has the strongest immunogenicity and can activate antibody-dependent cytotoxic T cells [<xref rid="B84-vaccines-13-00198" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-13-00198" ref-type="bibr">85</xref>]. NP is more conserved and induces a highly cross-reactive antibody response [<xref rid="B86-vaccines-13-00198" ref-type="bibr">86</xref>]. It has been reported that immunization with NP can induce a protective immune response that increases the survival of mice following challenges with a lethal dose of orthohantavirus [<xref rid="B87-vaccines-13-00198" ref-type="bibr">87</xref>]. Therefore, NP has become an attractive candidate antigen for orthohantavirus vaccine. Presently, there is no evidence that the protein encoded by the L segment induces an immune response during orthohantavirus infection.</p><p>Orthohantavirus infection is marked by high levels of virus-specific IgM detected at disease onset in humans. After initial infection, the viral load increases in the host, stimulating the production and rising titers of virus-specific antibodies. Serum virus-specific IgM usually peaks 7&#x02013;11 days after onset and declines during the convalescent phase, usually coinciding with the rise of IgG [<xref rid="B88-vaccines-13-00198" ref-type="bibr">88</xref>]. Orthohantavirus can induce early IgG1 responses that increase with disease progression. IgG2 usually remains unchanged during infection [<xref rid="B89-vaccines-13-00198" ref-type="bibr">89</xref>]. IgG3 significantly increases in the clinical course, peaking during the convalescent phase and then declining gradually decades after infection (<xref rid="vaccines-13-00198-f003" ref-type="fig">Figure 3</xref>). Orthohantavirus-specific antibodies, especially IgG, can persist for up to 34 years after natural infection [<xref rid="B90-vaccines-13-00198" ref-type="bibr">90</xref>]. No correlation has been found between IgG subclass levels and disease severity.</p><p>In orthohantavirus infection, cellular immunity may be part of the complex immune response in affected human organs. Both HFRS and HPS are marked by robust cytotoxic T lymphocyte (CTL) responses [<xref rid="B92-vaccines-13-00198" ref-type="bibr">92</xref>]. During orthohantavirus clearance, lasting CD8+ T-cell responses occur [<xref rid="B93-vaccines-13-00198" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-13-00198" ref-type="bibr">94</xref>] without increases in neutralizing antibodies titers, which are mediated by cytotoxic CD8+ T cells. Orthohantavirus-infected cells are protected from cytotoxic lymphocyte-mediated apoptosis by high levels of granzyme B and perforin [<xref rid="B15-vaccines-13-00198" ref-type="bibr">15</xref>,<xref rid="B95-vaccines-13-00198" ref-type="bibr">95</xref>]. The immune response to hantaviruses is characterized by a balanced Th1/Th2 response, as evidenced by cytokine profiles in sera. This type of response is aimed at promoting a less harmful and more controlled immune response [<xref rid="B96-vaccines-13-00198" ref-type="bibr">96</xref>]. In HPS, inactivation of Tregs not only reduced viral RNA in lungs and virus shedding in rats but also decreased lung lesions [<xref rid="B97-vaccines-13-00198" ref-type="bibr">97</xref>]. Orthohantaviruses can be effectively combated through the activation of cytotoxic T cells and the subsequent generation of cross-protection. Therefore, in evaluating vaccine effects, in addition to neutralizing antibodies, the following cellular immune indicators are included: the proliferation ability of specific T lymphocytes, the levels of cytokines secreted by specific T lymphocytes, the killing ability of CD8+ CTLs on orthohantavirus-infected cells, and particularly the number and function of memory T cells, which are for long-term immune protection.</p></sec></sec><sec id="sec2-vaccines-13-00198"><title>2. Vaccines Against Orthohantaviruses</title><sec id="sec2dot1-vaccines-13-00198"><title>2.1. Inactivated Vaccines</title><p>An inactivated vaccine was the pioneering orthohantavirus vaccine used to prevent HFRS in endemic regions. Inactivated vaccines are generated by subjecting a pathogen to heat or chemical treatments, which prevent replication while preserving immunogenicity, allowing the human immune system to recognize and respond to the pathogen. This methodology is well established, efficient, and cost-effective, leading to widespread adoption. Since the discovery of HTNV in 1976, researchers have explored the potential of orthohantavirus vaccines, primarily focusing on inactivated vaccines. However, vaccine development was limited due to challenges in virus isolation, large-scale viral culture, and biosecurity measures.</p><p>In 1988, South Korea successfully developed an inactivated vaccine named Hantavax using cultured brain cells of suckling mice infected with HTNV [<xref rid="B98-vaccines-13-00198" ref-type="bibr">98</xref>]. High-risk individuals, such as military personnel and rural residents who frequently encounter rodents, receive this inactivated vaccine [<xref rid="B99-vaccines-13-00198" ref-type="bibr">99</xref>]. The South Korean military implemented additional preventive measures, including avoiding training sites in areas with suspected elevated HFRS risks, rodent eradication, and clearing bushes or tall grass in nearby environments [<xref rid="B100-vaccines-13-00198" ref-type="bibr">100</xref>]. Following these interventions, the incidence of HFRS within the military exhibited a declining trend, starting from the 2000s [<xref rid="B101-vaccines-13-00198" ref-type="bibr">101</xref>]. A trial enrolled 3900 subjects to evaluate Hantavax efficacy, observing no confirmed HFRS cases among 1900 Hantavax vaccinees, while 20 cases were observed among 2000 non-vaccinated controls [<xref rid="B102-vaccines-13-00198" ref-type="bibr">102</xref>]. However, a small-scale controlled study indicated that Hantavax elicited only low levels of neutralizing antibodies and provided limited protection [<xref rid="B103-vaccines-13-00198" ref-type="bibr">103</xref>]. A retrospective study suggested that while Hantavax might reduce the severity of acute kidney injury, it did not significantly prevent the progression of HFRS [<xref rid="B101-vaccines-13-00198" ref-type="bibr">101</xref>]. Comparative analysis revealed distinct patterns of disease severity between a Hantavax-vaccinated group and an unvaccinated group [<xref rid="B104-vaccines-13-00198" ref-type="bibr">104</xref>]. To enhance the efficacy of vaccination, in 2018, the Korean Ministry of Food and Drug Safety officially announced an increase in the total dosage regimen of the inactivated vaccine from three to four doses [<xref rid="B105-vaccines-13-00198" ref-type="bibr">105</xref>]. A multicenter phase III clinical trial of a modified schedule (3 + 1 vaccination at 0, 1, 2, and 13 months) (NCT 02553837) revealed that Hantavax demonstrated a high seroconversion rate following the three-dose initial vaccination series. Furthermore, an additional dose administered 11 months later resulted in significant booster effects [<xref rid="B106-vaccines-13-00198" ref-type="bibr">106</xref>]. Despite ongoing debates about the protective efficacy and cost-effectiveness of vaccines since their widespread implementation [<xref rid="B103-vaccines-13-00198" ref-type="bibr">103</xref>], the use of inactivated vaccines for prevention in high-incidence areas of HFRS remains a crucial and viable option for public health [<xref rid="B107-vaccines-13-00198" ref-type="bibr">107</xref>].</p><p>In 1993, China approved its first inactivated orthohantavirus vaccine for clinical use, and in 1995, the vaccination program was launched in regions with a high incidence of HFRS [<xref rid="B99-vaccines-13-00198" ref-type="bibr">99</xref>,<xref rid="B108-vaccines-13-00198" ref-type="bibr">108</xref>]. A bivalent inactivated vaccine targeting SEOV and HTNV was developed in 1994 and subsequently incorporated in the Chinese Expanded Program on Immunization (EPI) in 2003. This bivalent vaccine is administered annually to residents aged 16&#x02013;60 years in endemic areas, with approximately 2 million doses distributed nationwide [<xref rid="B107-vaccines-13-00198" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-13-00198" ref-type="bibr">108</xref>]. Following the introduction of this vaccine, the incidence of HFRS decreased from 37,814 cases in 2000 to 11,248 cases in 2007 [<xref rid="B108-vaccines-13-00198" ref-type="bibr">108</xref>]. To date, four vaccines have been produced in China: three monovalent Hantaan vaccines (gerbil kidney cell vaccine, hamster kidney cell vaccine, and mouse brain vaccine) and one bivalent gerbil kidney cell vaccine against HTNV and SEOV [<xref rid="B109-vaccines-13-00198" ref-type="bibr">109</xref>]. The inactivated HTNV vaccine has demonstrated the potential to induce high titers of neutralizing antibodies and stimulate specific humoral and cellular immune responses in BALB/c mice against the prevalent HTNV strain [<xref rid="B110-vaccines-13-00198" ref-type="bibr">110</xref>]. A recent model suggests that enhancing vaccination coverage and reducing rodent populations, particularly wild mice, are critical strategies for decreasing HFRS infections [<xref rid="B111-vaccines-13-00198" ref-type="bibr">111</xref>]. The sustained implementation of bivalent inactivated vaccine programs in high-prevalence regions in China has been a critical strategy to reduce the incidence of HFRS. Over the last five years, this approach has contributed to maintaining the annual number of HFRS cases below 10,000.</p><p>Russia reports approximately 7300 cases of HFRS annually, with an overall case fatality rate (CFR) of 0.4%. PUUV is the causative agent for nearly all HFRS cases identified in western regions of Russia [<xref rid="B112-vaccines-13-00198" ref-type="bibr">112</xref>]. In 2020, Russian researchers reported the results of preclinical studies for a candidate polyvalent HFRS vaccine. The inactivated polyvalent vaccine, based on Puumala (strain PUU-TKD/VERO), Hantaan (strain HTN-P88/VERO), and Sochi (strain DOB-SOCHI/VERO) viruses, remains in the preclinical phase [<xref rid="B113-vaccines-13-00198" ref-type="bibr">113</xref>]. A recent study demonstrated that different adjuvants exert distinct effects on the immunogenicity of the PUUV vaccine [<xref rid="B114-vaccines-13-00198" ref-type="bibr">114</xref>]. Compared to the traditionally used aluminum hydroxide, both the B subunit of heat-labile enterotoxins and plant virus-based spherical particles significantly enhance the humoral immune response elicited by the vaccine. Low-endotoxicity lipopolysaccharide not only boosts the immune response but also maintains the vaccine&#x02019;s immunogenicity for at least one year of storage [<xref rid="B114-vaccines-13-00198" ref-type="bibr">114</xref>]. These findings suggest potential improvements for inactivated vaccines; however, no new inactivated vaccines are expected to become clinically available in the near future.</p></sec><sec id="sec2dot2-vaccines-13-00198"><title>2.2. Viral Vector-Based Vaccines</title><p>Viral vector-based vaccines, particularly those expressing orthohantavirus antigens, have demonstrated the ability to elicit both humoral and cellular immune responses without the need for adjuvants. Preclinical animal models have shown that this approach can result in a robust and favorable immune response against orthohantavirus infection. Recombinant adenoviruses (AdVs) expressing GnS0.7, a fusion protein containing Gc and truncated NP, have been constructed and shown to induce strong HTNV-specific immune responses in mice [<xref rid="B115-vaccines-13-00198" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-13-00198" ref-type="bibr">116</xref>]. Moreover, given that heat-shock proteins (HSPs) exhibit adjuvant properties when administered as fusion proteins to boost vaccination efficacy, a recombinant AdV vector named rAdV-GnS0.7- pCAG-HSP70C was constructed. This vector was engineered by fusing the C-terminal region of the HSP70 gene with the HTNV Gn protein and a 0.7-kilobase fragment of the NP gene [<xref rid="B117-vaccines-13-00198" ref-type="bibr">117</xref>]. Animal protection experiments demonstrated that this recombinant adenovirus enhanced humoral and cellular immune response [<xref rid="B117-vaccines-13-00198" ref-type="bibr">117</xref>]. Non-replicating AdV vectors expressing Andes virus (ANDV) NP or GP have been constructed to protect Syrian hamsters from lethal ANDV infection by producing strong cytotoxic T-lymphocyte responses directed to orthohantavirus proteins and without detectable neutralizing antibodies [<xref rid="B118-vaccines-13-00198" ref-type="bibr">118</xref>]. Syrian hamsters immunized with a single dose of recombinant vesicular stomatitis virus (VSV) vector-based vaccine expressing ANDV surface glycoprotein were protected against lethal ANDV infection challenges [<xref rid="B119-vaccines-13-00198" ref-type="bibr">119</xref>]. A replication-competent recombinant VSV vaccine expressing the GP of ANDV instead of the native VSV GP has also been developed [<xref rid="B120-vaccines-13-00198" ref-type="bibr">120</xref>]. This vaccine was highly efficacious in the Syrian hamster model of HPS within 6 months, but the protective effect decreased one year later [<xref rid="B120-vaccines-13-00198" ref-type="bibr">120</xref>]. Recombinant vaccines constructed respectively against ANDV and SNV viruses were found to produce cross-immunity against each other [<xref rid="B121-vaccines-13-00198" ref-type="bibr">121</xref>]. In 2024, a recombinant (r) rVSV-HTNV-GP was also engineered and provided longer-term protection against HTNV infection than inactivated vaccines [<xref rid="B122-vaccines-13-00198" ref-type="bibr">122</xref>].</p><p>The emergence of viral vector-based vaccines, such as recombinant adenovirus type 5 (Ad5)-vectored COVID-19 vaccine [<xref rid="B123-vaccines-13-00198" ref-type="bibr">123</xref>], has sparked concerns about the influence of pre-existing immunity to the vaccine vector on vaccine efficacy [<xref rid="B124-vaccines-13-00198" ref-type="bibr">124</xref>]. This issue became especially pertinent in the aftermath of the COVID-19 pandemic and overlapping endemic areas. A previous study indicated that pre-existing vaccinia immunity can diminish the efficacy of recombinant vaccinia vaccines for HTNV [<xref rid="B125-vaccines-13-00198" ref-type="bibr">125</xref>]. Similarly, pre-existing immunity to the AdV vector has been observed to affect both immunogenicity and efficacy, particularly at lower vaccine doses [<xref rid="B126-vaccines-13-00198" ref-type="bibr">126</xref>]. Repeated immunization can improve vaccine protective efficacy, but whether consecutive immunization of a vaccine based on the same viral vector would be effective in the same population due to pre-existing immunity is uncertain. Investigating the pre-existing immune status of the viral vector in the population in advance may help select more advantageous virus vectors, such as AdV 35 vs. AdV 5, and using higher vaccine doses may overcome pre-existing immunity to the virus vector [<xref rid="B126-vaccines-13-00198" ref-type="bibr">126</xref>]. Heterologous sequential immunization can utilize different antigen types, delivery platforms, and administration routes to induce multifaceted immune responses, which may be a practical strategy [<xref rid="B127-vaccines-13-00198" ref-type="bibr">127</xref>].</p><p>There is a need to address safety issues associated with the administration of replicating vaccines in humans [<xref rid="B128-vaccines-13-00198" ref-type="bibr">128</xref>]. One concern is the potential neurovirulence of VSV. The possibility of generating a virulent phenotype through recombination of the genomes of these virus vectors and circulating viruses cannot be ignored [<xref rid="B129-vaccines-13-00198" ref-type="bibr">129</xref>]. Another consideration is vaccine safety in immunocompromised individuals, as they can replicate efficiently. In regard to large-scale use of viral vector-based vaccines, severe and unexplained conditions must be considered. For instance, a phase III clinical trial of a COVID-19 vaccine was paused due to AdV-induced immune thrombosis and thrombocytopenia syndrome [<xref rid="B130-vaccines-13-00198" ref-type="bibr">130</xref>].</p></sec><sec id="sec2dot3-vaccines-13-00198"><title>2.3. Virus-like Particles</title><p>Virus-like particles (VLPs) are composed of repetitive viral structural proteins with inherent self-assembly characteristics. They resemble natural virus particles, but lack infectious genetic material [<xref rid="B131-vaccines-13-00198" ref-type="bibr">131</xref>]. VLPs can elicit potent antiviral humoral and cellular immune responses because they can mimic the virus and are efficiently taken up, rapidly internalized, and processed by antigen-presenting cells (APCs) [<xref rid="B132-vaccines-13-00198" ref-type="bibr">132</xref>,<xref rid="B133-vaccines-13-00198" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-13-00198" ref-type="bibr">134</xref>]. VLPs have been developed for several viruses, such as hepatitis B [<xref rid="B132-vaccines-13-00198" ref-type="bibr">132</xref>], HIV-1 [<xref rid="B133-vaccines-13-00198" ref-type="bibr">133</xref>], and HPV [<xref rid="B134-vaccines-13-00198" ref-type="bibr">134</xref>]. Therefore, VLPs have garnered great attention in the development of hantavirus vaccines.</p><p>Studies have demonstrated that chimeric VLPs devoid of orthohantavirus nucleic acids can elicit an orthohantavirus-specific immune response from the host. VLPs were engineered using hepatitis B virus (HBV) capsids, incorporating a 120-amino acid segment from the NP of highly pathogenic DOBV and HTNV. Immunization with these chimeric VLPs induced a high-titer, cross-reactive NP-specific antibody response in both BALB/c and C57BL/6 mice [<xref rid="B135-vaccines-13-00198" ref-type="bibr">135</xref>,<xref rid="B136-vaccines-13-00198" ref-type="bibr">136</xref>]. Additionally, a 99-amino acid-long segment of Gc protein from PUUV was inserted into the major capsid protein VP1 of hamster polyomavirus to create VLPs. These chimeric VLPs induced an efficient insert-specific antibody response in immunized mice [<xref rid="B137-vaccines-13-00198" ref-type="bibr">137</xref>]. Recombinant HTNV-VLPs were produced by co-expressing HTNV-NP and GP in Chinese hamster ovary (CHO) cells using a human IgG heavy chain expression vector. These VLPs demonstrated that intramuscular and subcutaneous immunizations could effectively stimulate specific humoral and cellular responses against HTNV-NP and GP comparable to those induced by an inactivated bivalent orthohantavirus vaccine [<xref rid="B132-vaccines-13-00198" ref-type="bibr">132</xref>,<xref rid="B138-vaccines-13-00198" ref-type="bibr">138</xref>]. Furthermore, reconstructed VLPs incorporating CD40 ligand or granulocyte&#x02013;macrophage colony-stimulating factor (GM-CSF) were created to enhance immunogenicity. The study showed that these modified VLPs significantly increased neutralizing antibody titers against HTNV and provided stable, long-term protection for up to 6 months post-immunization in mice [<xref rid="B139-vaccines-13-00198" ref-type="bibr">139</xref>].</p><p>VLPs have demonstrated potential for controlling orthohantavirus infection [<xref rid="B140-vaccines-13-00198" ref-type="bibr">140</xref>]. VLPs lack genetic material, which reduces the risk of adverse effects and is intrinsically safer than attenuated virus vaccines [<xref rid="B140-vaccines-13-00198" ref-type="bibr">140</xref>]. However, VLPs may degrade more rapidly than those derived from live organisms. Unlike attenuated organisms, VLPs lack the inherent pro-inflammatory properties of live vaccines. Therefore, optimizing VLP stability and effectiveness remains a subject for further study. Combining VLPs with immunopotentiators may be a promising approach to enhance vaccine efficacy.</p></sec><sec id="sec2dot4-vaccines-13-00198"><title>2.4. Subunit Vaccines</title><p>Subunit vaccines contain specific microbial components, such as proteins or surface antigens, that can induce neutralizing antibodies. Recombinant protein subunit vaccines avoid potential issues with purified macromolecule subunit vaccines, including co-purification of undesired contaminants or reversal of toxoids to toxigenic forms and interference between multivalent formulation components [<xref rid="B141-vaccines-13-00198" ref-type="bibr">141</xref>,<xref rid="B142-vaccines-13-00198" ref-type="bibr">142</xref>,<xref rid="B143-vaccines-13-00198" ref-type="bibr">143</xref>]. Thus, recombinant DNA technology has been proposed for expressing orthohantavirus proteins for hantavirus subunit vaccine development [<xref rid="B144-vaccines-13-00198" ref-type="bibr">144</xref>,<xref rid="B145-vaccines-13-00198" ref-type="bibr">145</xref>]. Recombinant DOBV nucleocapsid proteins (rNPs) in mice induced a strong NP-specific IgG response and mixed Th1/Th2-cell involvement [<xref rid="B146-vaccines-13-00198" ref-type="bibr">146</xref>]. DOBV rNPs conjugated with recombinant rP40 (the Klebsiella pneumoniae outer membrane protein A) showed higher NP-specific antibody responses. Immunogenicity of PUUV rNP&#x02013;rP40 was characterized [<xref rid="B147-vaccines-13-00198" ref-type="bibr">147</xref>]. Recombinant PUUV proteins were expressed in E. coli 200. The truncated construct, P40-Puu118, gave high antibody titers after two doses and 100% protection after three doses, suggesting potential as a subunit vaccine against PUUV [<xref rid="B148-vaccines-13-00198" ref-type="bibr">148</xref>].</p><p>Recent years have witnessed significant advancements in both immune protection technology and bioinformatics, particularly high-throughput sequencing technology, accelerating the development of multi-epitope subunit vaccines through the reverse-vaccinology approach. In 2022, Ismail screened 340 epitopes from the Virus Pathogen Database and Analysis Resource (ViPR), identifying 10 epitopes for potential inclusion in a potent multi-antigenic epitope subunit vaccine. These epitopes were linked through specific GPGPG linkers to create a computationally designed vaccine [<xref rid="B149-vaccines-13-00198" ref-type="bibr">149</xref>]. This vaccine was then computationally combined with three different adjuvants to stimulate immune responses. A major limitation of that study is the lack of experimental validation.</p></sec><sec id="sec2dot5-vaccines-13-00198"><title>2.5. Nucleic Acid Vaccines</title><p>The third-generation nucleic acid vaccine has shown promise in inducing both humoral and cellular immunity without requiring additional immunization, making it a potentially effective vaccination strategy for a variety of viral infections [<xref rid="B150-vaccines-13-00198" ref-type="bibr">150</xref>]. This approach has demonstrated good safety, as the vaccines are replication-defective and cannot revert to virulence or transmit from person to person or into the environment [<xref rid="B151-vaccines-13-00198" ref-type="bibr">151</xref>]. Moreover, the nucleic acid vaccine offers an easy method for constructing multivalent vaccines [<xref rid="B91-vaccines-13-00198" ref-type="bibr">91</xref>].</p><p>A DNA vaccine expressing HTNV M gene products, G<sub>1</sub> and G<sub>2</sub>, was developed [<xref rid="B152-vaccines-13-00198" ref-type="bibr">152</xref>,<xref rid="B153-vaccines-13-00198" ref-type="bibr">153</xref>]. It was shown that this vaccine induced high levels of neutralizing antibodies and provided complete protection against HTNV, SEOV, and DOBV infections in hamsters [<xref rid="B154-vaccines-13-00198" ref-type="bibr">154</xref>]. The phase I clinical trial demonstrated the safety of DNA vaccines encoding the HTNV or PUUV M-segment delivered by electroporation separately or as a mixture [<xref rid="B154-vaccines-13-00198" ref-type="bibr">154</xref>]. The mixture showed safety and induced high-frequency immune responses in the phase IIa clinical trial [<xref rid="B155-vaccines-13-00198" ref-type="bibr">155</xref>]. A DNA vaccine based on the ANDV M gene and a DNA plasmid encoding both the ANDV and HTNV M genes induced high-titer neutralizing antibodies in rabbits and nonhuman primates [<xref rid="B156-vaccines-13-00198" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-13-00198" ref-type="bibr">157</xref>]. Recently, a DNA vaccine developed using the complete M gene of SNV was engineered, and it successfully elicited high-titer neutralizing antibodies [<xref rid="B71-vaccines-13-00198" ref-type="bibr">71</xref>]. These studies suggest that DNA vaccines can provide cross-protection against various species of orthohantaviruses [<xref rid="B152-vaccines-13-00198" ref-type="bibr">152</xref>,<xref rid="B158-vaccines-13-00198" ref-type="bibr">158</xref>]. Interestingly, the HPS vaccine elicited immune responses against SNV and ANDV, whereas it did not induce reactions against HTNV and PUUV. In contrast, the HFRS vaccine triggered responses to HTNV and PUUV, but was ineffective against ANDV and SNV. These findings highlight distinct differences in reactivity among various orthohantavirus species [<xref rid="B71-vaccines-13-00198" ref-type="bibr">71</xref>].</p><p>A DNA vaccine was constructed incorporating the fusion of HTNV NP and GP with the extracellular region of cytotoxic T lymphocyte-associated antigen 4 (eCTLA-4), aimed at targeting antigen-presenting cells (APCs). This eCTLA-4 fusion approach led to improved antibody and cellular immune responses in mice [<xref rid="B159-vaccines-13-00198" ref-type="bibr">159</xref>]. Moreover, a DNA vaccine was developed that targets the hantavirus glycoprotein N-terminal (Gn) or Gc and is presented to the major histocompatibility complex class II compartment by fusing the glycoproteins with lysosome-associated membrane protein 1 (LAMP1) [<xref rid="B160-vaccines-13-00198" ref-type="bibr">160</xref>,<xref rid="B161-vaccines-13-00198" ref-type="bibr">161</xref>]. By altering the antigen-processing pathway for major histocompatibility complex II, LAMP1 contributed to enhanced long-term humoral immunity [<xref rid="B162-vaccines-13-00198" ref-type="bibr">162</xref>].</p><p>Nucleic acid vaccines, particularly DNA vaccines, are at the forefront against orthohantaviruses, with several in clinical trials (<xref rid="vaccines-13-00198-t001" ref-type="table">Table 1</xref>). RNA vaccines have also shown promise. Studies have compared non-modified and modified mRNA vaccines against ANDV, evaluating immunogenicity, germinal center induction, antibody responses, and protective efficacy. The results showed that both versions provided protection without significant differences in immunogenicity or protection in rodents [<xref rid="B163-vaccines-13-00198" ref-type="bibr">163</xref>]. Three novel nucleic acid vaccine candidates&#x02014;mRNA, naked DNA, and DNA-LNP encoding HTNV glycoproteins&#x02014;were assessed in mice. All candidates induced robust and sustained immune responses, matching the protective efficacy of inactivated vaccines. Notably, mRNA triggered stronger T-helper 1 cell responses, while DNA-LNP produced higher neutralizing antibodies compared to inactivated vaccines [<xref rid="B164-vaccines-13-00198" ref-type="bibr">164</xref>].</p></sec></sec><sec id="sec3-vaccines-13-00198"><title>3. Prospect of Vaccine Development and Application</title><p>Historically, inactivated vaccines have been the dominant approach for designing orthohantavirus vaccines, due to their relative ease of establishment. However, concerns about nondurable immunity and complex immune components have prompted exploration of alternative vaccine types, including viral vector-based vaccines, virus-like particles, and subunit vaccines. Advances in bioinformatics and computational biology have significantly accelerated this development [<xref rid="B165-vaccines-13-00198" ref-type="bibr">165</xref>,<xref rid="B166-vaccines-13-00198" ref-type="bibr">166</xref>,<xref rid="B167-vaccines-13-00198" ref-type="bibr">167</xref>]. Comprehensive computational analyses of orthohantavirus motifs and codon usage have provided insights into host immune regulation and evolutionary history, aiding identification of conserved epitopes and antigenic regions crucial for robust immune responses [<xref rid="B168-vaccines-13-00198" ref-type="bibr">168</xref>,<xref rid="B169-vaccines-13-00198" ref-type="bibr">169</xref>]. Molecular docking and dynamic simulations evaluate binding affinity between vaccine candidate proteins and host immune receptors [<xref rid="B170-vaccines-13-00198" ref-type="bibr">170</xref>], while immune simulation analysis can predict natural immune responses [<xref rid="B165-vaccines-13-00198" ref-type="bibr">165</xref>,<xref rid="B171-vaccines-13-00198" ref-type="bibr">171</xref>]. Several multi-epitope subunit vaccines for cross-protection against orthohantaviruses, such as HTNV and PUUV, have been developed based on immunoinformatic approaches [<xref rid="B149-vaccines-13-00198" ref-type="bibr">149</xref>,<xref rid="B165-vaccines-13-00198" ref-type="bibr">165</xref>,<xref rid="B166-vaccines-13-00198" ref-type="bibr">166</xref>,<xref rid="B170-vaccines-13-00198" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-13-00198" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-13-00198" ref-type="bibr">172</xref>,<xref rid="B173-vaccines-13-00198" ref-type="bibr">173</xref>]. However, all computationally designed vaccines require experimental validation before clinical application.</p><p>In addition to vaccine types and selected epitopes, different adjuvants and immunization strategies are crucial. Compared to traditional mineral adjuvants, particulate adjuvants, and protein adjuvants, lipopolysaccharide has demonstrated more pronounced stimulation of immunogenicity [<xref rid="B114-vaccines-13-00198" ref-type="bibr">114</xref>]. An immunoinformatic-designed vaccine tested three different adjuvants&#x02014;TLR4-agonist adjuvant, &#x003b2;-defensin, and 50S ribosomal protein L7/L12&#x02014;aiming to enhance immune responses and evaluate the vaccine&#x02019;s efficacy with each adjuvant [<xref rid="B149-vaccines-13-00198" ref-type="bibr">149</xref>]. Various vaccination routes, including intramuscular injection and mucosal vaccination, have been explored [<xref rid="B174-vaccines-13-00198" ref-type="bibr">174</xref>]. Moreover, an effective immunization schedule is essential, especially when a single dose of vaccine does not provide adequate protection. For instance, in March 2018, the Korean Central Pharmaceutical Affairs Council of the Ministry of Food and Drug Safety (MFDS) increased the number of Hantavax inoculations from three to four. Heterologous sequential immunization may serve as a practical strategy to boost immune efficacy.</p><p>Testing and approving orthohantavirus vaccines presents unique challenges due to the limited patient population and difficulties in conducting large-scale clinical trials. For other rare diseases, researchers often rely on adaptive trial designs to assess vaccine efficacy, allowing modifications based on interim results or surrogate endpoints like immune response markers. However, these markers are not universally recognized as reliable surrogates for clinical endpoints. Initially, the seropositivity rates from four major methods used to measure vaccine immunogenicity varied significantly [<xref rid="B106-vaccines-13-00198" ref-type="bibr">106</xref>]. Moreover, maintaining immunogenicity does not necessarily equate to vaccine effectiveness, which remains to be validated. Identifying a reliable surrogate endpoint could enable regulatory agencies such as the FDA and EMA to employ accelerated approval pathways, contingent on post-marketing surveillance, thereby expediting access to these vaccines.</p></sec><sec sec-type="conclusions" id="sec4-vaccines-13-00198"><title>4. Conclusions</title><p>As a significant global public health concern, the research and development of orthohantavirus vaccines hold considerable practical importance. While notable advancements have been made across various vaccine platforms, including inactivated, subunit, viral vector, VLP, and nucleic acid vaccines, several challenges remain. These include inadequate immunogenicity, limited broad-spectrum protective efficacy, and complexities in manufacturing and distribution. Moving forward, by refining vaccine design, enhancing vaccination strategies, establishing rigorous evaluation criteria, and fostering international collaboration, it is anticipated that orthohantavirus vaccine research will achieve critical breakthroughs. Ultimately, the development of a safe and effective vaccine will provide a robust tool for preventing and controlling orthohantavirus infections, thereby making a substantial contribution to global public health security.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, H.J.; validation, S.C., L.W., H.D. and H.J.; investigation, S.C. and L.W.; data curation, S.C. and L.W.; writing&#x02014;original draft preparation, S.C. and L.W.; writing&#x02014;review and editing, H.J. and H.D.; visualization, S.C.; software, S.C.; supervision, H.J. and H.D.; funding acquisition, H.J. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ad5</td><td align="left" valign="middle" rowspan="1" colspan="1">adenovirus type 5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APCs</td><td align="left" valign="middle" rowspan="1" colspan="1">antigen-presenting cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ANDV</td><td align="left" valign="middle" rowspan="1" colspan="1">Andes virus (<italic toggle="yes">Orthohantavirus andesense</italic>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHO</td><td align="left" valign="middle" rowspan="1" colspan="1">Chinese hamster ovary</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">COVID-19</td><td align="left" valign="middle" rowspan="1" colspan="1">coronavirus disease 2019</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTL</td><td align="left" valign="middle" rowspan="1" colspan="1">cytotoxic T lymphocyte</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOBV</td><td align="left" valign="middle" rowspan="1" colspan="1">Dobrava-Belgrade virus (<italic toggle="yes">Orthohantavirus dobravaense</italic>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EPI</td><td align="left" valign="middle" rowspan="1" colspan="1">Expanded Program on Immunization</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">granulocyte&#x02013;macrophage colony-stimulating factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GP</td><td align="left" valign="middle" rowspan="1" colspan="1">glycoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HFRS</td><td align="left" valign="middle" rowspan="1" colspan="1">hemorrhagic fever with renal syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HPS</td><td align="left" valign="middle" rowspan="1" colspan="1">hantavirus pulmonary syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HSPs</td><td align="left" valign="middle" rowspan="1" colspan="1">heat-shock proteins</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTNV</td><td align="left" valign="middle" rowspan="1" colspan="1">Hantaan virus (<italic toggle="yes">Orthohantavirus hantanense</italic>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NE</td><td align="left" valign="middle" rowspan="1" colspan="1">nephropathia epidemica</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NP</td><td align="left" valign="middle" rowspan="1" colspan="1">nucleocapsid protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PUUV</td><td align="left" valign="middle" rowspan="1" colspan="1">Puumala virus (<italic toggle="yes">Orthohantavirus puumalaense</italic>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RdRp</td><td align="left" valign="middle" rowspan="1" colspan="1">RNA-dependent RNA polymerase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SEOV</td><td align="left" valign="middle" rowspan="1" colspan="1">Seoul virus (<italic toggle="yes">Orthohantavirus seoulense</italic>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNV</td><td align="left" valign="middle" rowspan="1" colspan="1">Sin Nombre virus (<italic toggle="yes">Orthohantavirus sinnombreense</italic>)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VLPs</td><td align="left" valign="middle" rowspan="1" colspan="1">virus-like particles</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VSV</td><td align="left" valign="middle" rowspan="1" colspan="1">vesicular stomatitis virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WHO</td><td align="left" valign="middle" rowspan="1" colspan="1">World Health Organization</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vaccines-13-00198"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>ICTV, International Committee on Taxonomy of Viruses</collab>
</person-group><article-title>Virus Taxonomy: 2023 Release</article-title><comment>Available online: <ext-link xlink:href="https://ictv.global/taxonomy" ext-link-type="uri">https://ictv.global/taxonomy</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-03">(accessed on 3 February 2025)</date-in-citation></element-citation></ref><ref id="B2-vaccines-13-00198"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuhn</surname><given-names>J.H.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
</person-group><article-title>A Brief History of Bunyaviral Family Hantaviridae</article-title><source>Diseases</source><year>2023</year><volume>11</volume><elocation-id>38</elocation-id><pub-id pub-id-type="doi">10.3390/diseases11010038</pub-id><pub-id pub-id-type="pmid">36975587</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00198"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noack</surname><given-names>D.</given-names></name>
<name><surname>Goeijenbier</surname><given-names>M.</given-names></name>
<name><surname>Reusken</surname><given-names>C.</given-names></name>
<name><surname>Koopmans</surname><given-names>M.P.G.</given-names></name>
<name><surname>Rockx</surname><given-names>B.H.G.</given-names></name>
</person-group><article-title>Orthohantavirus Pathogenesis and Cell Tropism</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>399</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.00399</pub-id><pub-id pub-id-type="pmid">32903721</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00198"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Zheng</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Du</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Bai</surname><given-names>X.</given-names></name>
</person-group><article-title>Hantavirus infection: A global zoonotic challenge</article-title><source>Virol. Sin.</source><year>2017</year><volume>32</volume><fpage>32</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/s12250-016-3899-x</pub-id><pub-id pub-id-type="pmid">28120221</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00198"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borgman</surname><given-names>M.</given-names></name>
</person-group><article-title>The 1993 Hantavirus Pulmonary Syndrome Outbreak and Lessons for Today</article-title><source>Med. J.</source><year>2021</year><volume>PB 8-21-01/02/03</volume><fpage>22</fpage><lpage>27</lpage></element-citation></ref><ref id="B6-vaccines-13-00198"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riquelme</surname><given-names>R.</given-names></name>
<name><surname>Rioseco</surname><given-names>M.L.</given-names></name>
<name><surname>Bastidas</surname><given-names>L.</given-names></name>
<name><surname>Trincado</surname><given-names>D.</given-names></name>
<name><surname>Riquelme</surname><given-names>M.</given-names></name>
<name><surname>Loyola</surname><given-names>H.</given-names></name>
<name><surname>Valdivieso</surname><given-names>F.</given-names></name>
</person-group><article-title>Hantavirus pulmonary syndrome, Southern Chile, 1995-2012</article-title><source>Emerg. Infect. Dis.</source><year>2015</year><volume>21</volume><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.3201/eid2104.141437</pub-id><pub-id pub-id-type="pmid">25816116</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00198"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Milholland</surname><given-names>M.T.</given-names></name>
<name><surname>Castro-Arellano</surname><given-names>I.</given-names></name>
<name><surname>Suzan</surname><given-names>G.</given-names></name>
<name><surname>Garcia-Pena</surname><given-names>G.E.</given-names></name>
<name><surname>Lee</surname><given-names>T.E.</given-names><suffix>Jr.</suffix></name>
<name><surname>Rohde</surname><given-names>R.E.</given-names></name>
<name><surname>Alonso Aguirre</surname><given-names>A.</given-names></name>
<name><surname>Mills</surname><given-names>J.N.</given-names></name>
</person-group><article-title>Global Diversity and Distribution of Hantaviruses and Their Hosts</article-title><source>Ecohealth</source><year>2018</year><volume>15</volume><fpage>163</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/s10393-017-1305-2</pub-id><pub-id pub-id-type="pmid">29713899</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00198"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goodfellow</surname><given-names>S.M.</given-names></name>
<name><surname>Nofchissey</surname><given-names>R.A.</given-names></name>
<name><surname>Ye</surname><given-names>C.</given-names></name>
<name><surname>Banther-McConnell</surname><given-names>J.K.</given-names></name>
<name><surname>Suriyamongkol</surname><given-names>T.</given-names></name>
<name><surname>Cook</surname><given-names>J.A.</given-names></name>
<name><surname>Dunnum</surname><given-names>J.L.</given-names></name>
<name><surname>Mali</surname><given-names>I.</given-names></name>
<name><surname>Bradfute</surname><given-names>S.B.</given-names></name>
</person-group><article-title>A human pathogenic hantavirus circulates and is shed in taxonomically diverse rodent reservoirs</article-title><source>PLoS Pathog.</source><year>2025</year><volume>21</volume><elocation-id>e1012849</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1012849</pub-id><pub-id pub-id-type="pmid">39836687</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00198"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>H.</given-names></name>
<name><surname>Du</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>L.M.</given-names></name>
<name><surname>Wang</surname><given-names>P.Z.</given-names></name>
<name><surname>Bai</surname><given-names>X.F.</given-names></name>
</person-group><article-title>Hemorrhagic Fever with Renal Syndrome: Pathogenesis and Clinical Picture</article-title><source>Front. Cell Infect. Microbiol.</source><year>2016</year><volume>6</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2016.00001</pub-id><pub-id pub-id-type="pmid">26870699</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00198"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mart&#x000ed;nez</surname><given-names>V.P.</given-names></name>
<name><surname>Di Paola</surname><given-names>N.</given-names></name>
<name><surname>Alonso</surname><given-names>D.O.</given-names></name>
<name><surname>P&#x000e9;rez-Sautu</surname><given-names>U.</given-names></name>
<name><surname>Bellomo</surname><given-names>C.M.</given-names></name>
<name><surname>Iglesias</surname><given-names>A.A.</given-names></name>
<name><surname>Coelho</surname><given-names>R.M.</given-names></name>
<name><surname>L&#x000f3;pez</surname><given-names>B.</given-names></name>
<name><surname>Periolo</surname><given-names>N.</given-names></name>
<name><surname>Larson</surname><given-names>P.A.</given-names></name>
<etal/>
</person-group><article-title>&#x0201c;Super-Spreaders&#x0201d; and Person-to-Person Transmission of Andes Virus in Argentina</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2230</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2009040</pub-id><pub-id pub-id-type="pmid">33264545</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00198"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>D.O.</given-names></name>
<name><surname>P&#x000e9;rez-Sautu</surname><given-names>U.</given-names></name>
<name><surname>Bellomo</surname><given-names>C.M.</given-names></name>
<name><surname>Prieto</surname><given-names>K.</given-names></name>
<name><surname>Iglesias</surname><given-names>A.</given-names></name>
<name><surname>Coelho</surname><given-names>R.</given-names></name>
<name><surname>Periolo</surname><given-names>N.</given-names></name>
<name><surname>Domenech</surname><given-names>I.</given-names></name>
<name><surname>Talmon</surname><given-names>G.</given-names></name>
<name><surname>Hansen</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Person-to-Person Transmission of Andes Virus in Hantavirus Pulmonary Syndrome, Argentina, 2014</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>756</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.3201/eid2604.190799</pub-id><pub-id pub-id-type="pmid">32186494</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00198"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferr&#x000e9;s</surname><given-names>M.</given-names></name>
<name><surname>Mart&#x000ed;nez-Valdebenito</surname><given-names>C.</given-names></name>
<name><surname>Angulo</surname><given-names>J.</given-names></name>
<name><surname>Henr&#x000ed;quez</surname><given-names>C.</given-names></name>
<name><surname>Vera-Ot&#x000e1;rola</surname><given-names>J.</given-names></name>
<name><surname>Vergara</surname><given-names>M.J.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>J.</given-names></name>
<name><surname>Fern&#x000e1;ndez</surname><given-names>J.</given-names></name>
<name><surname>Sotomayor</surname><given-names>V.</given-names></name>
<name><surname>Vald&#x000e9;s</surname><given-names>M.F.</given-names></name>
<etal/>
</person-group><article-title>Mother-to-Child Transmission of Andes Virus through Breast Milk, Chile(1)</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>1885</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.3201/eid2608.200204</pub-id><pub-id pub-id-type="pmid">32687024</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00198"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>V.P.</given-names></name>
<name><surname>Bellomo</surname><given-names>C.</given-names></name>
<name><surname>San Juan</surname><given-names>J.</given-names></name>
<name><surname>Pinna</surname><given-names>D.</given-names></name>
<name><surname>Forlenza</surname><given-names>R.</given-names></name>
<name><surname>Elder</surname><given-names>M.</given-names></name>
<name><surname>Padula</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Person-to-person transmission of Andes virus</article-title><source>Emerg. Infect. Dis.</source><year>2005</year><volume>11</volume><fpage>1848</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.3201/eid1112.050501</pub-id><pub-id pub-id-type="pmid">16485469</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00198"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toledo</surname><given-names>J.</given-names></name>
<name><surname>Haby</surname><given-names>M.M.</given-names></name>
<name><surname>Reveiz</surname><given-names>L.</given-names></name>
<name><surname>Sosa Leon</surname><given-names>L.</given-names></name>
<name><surname>Angerami</surname><given-names>R.</given-names></name>
<name><surname>Aldighieri</surname><given-names>S.</given-names></name>
</person-group><article-title>Evidence for Human-to-Human Transmission of Hantavirus: A Systematic Review</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>226</volume><fpage>1362</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab461</pub-id><pub-id pub-id-type="pmid">34515290</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00198"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saavedra</surname><given-names>F.</given-names></name>
<name><surname>Diaz</surname><given-names>F.E.</given-names></name>
<name><surname>Retamal-Diaz</surname><given-names>A.</given-names></name>
<name><surname>Covian</surname><given-names>C.</given-names></name>
<name><surname>Gonzalez</surname><given-names>P.A.</given-names></name>
<name><surname>Kalergis</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Immune response during hantavirus diseases: Implications for immunotherapies and vaccine design</article-title><source>Immunology</source><year>2021</year><volume>163</volume><fpage>262</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/imm.13322</pub-id><pub-id pub-id-type="pmid">33638192</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00198"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Korean hemorrhagic fever</article-title><source>Prog. Med. Virol.</source><year>1982</year><volume>28</volume><fpage>96</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">6124025</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00198"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Raw</surname><given-names>N.</given-names></name>
</person-group><article-title>Trench Nephritis: A Record of Five Cases</article-title><source>Br. Med. J.</source><year>1915</year><volume>2</volume><fpage>468</fpage><pub-id pub-id-type="doi">10.1136/bmj.2.2856.468</pub-id><pub-id pub-id-type="pmid">20767829</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00198"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pruitt</surname><given-names>F.W.</given-names></name>
<name><surname>Cleve</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Epidemic hemorrhagic fever</article-title><source>Am. J. Med. Sci.</source><year>1953</year><volume>225</volume><fpage>660</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1097/00000441-195306000-00011</pub-id><pub-id pub-id-type="pmid">13057861</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00198"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kabwe</surname><given-names>E.</given-names></name>
<name><surname>Shamsutdinov</surname><given-names>A.F.</given-names></name>
<name><surname>Suleimanova</surname><given-names>S.</given-names></name>
<name><surname>Martynova</surname><given-names>E.V.</given-names></name>
<name><surname>Ismagilova</surname><given-names>R.K.</given-names></name>
<name><surname>Shakirova</surname><given-names>V.G.</given-names></name>
<name><surname>Savitskaya</surname><given-names>T.A.</given-names></name>
<name><surname>Isaeva</surname><given-names>G.S.</given-names></name>
<name><surname>Rizvanov</surname><given-names>A.A.</given-names></name>
<name><surname>Khaiboullina</surname><given-names>S.F.</given-names></name>
<etal/>
</person-group><article-title>Puumala Orthohantavirus Reassortant Genome Variants Likely Emerging in the Watershed Forests</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>1018</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24021018</pub-id><pub-id pub-id-type="pmid">36674534</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00198"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vaheri</surname><given-names>A.</given-names></name>
<name><surname>Henttonen</surname><given-names>H.</given-names></name>
<name><surname>Mustonen</surname><given-names>J.</given-names></name>
</person-group><article-title>Hantavirus Research in Finland: Highlights and Perspectives</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1452</elocation-id><pub-id pub-id-type="doi">10.3390/v13081452</pub-id><pub-id pub-id-type="pmid">34452318</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00198"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>A.S.</given-names></name>
<name><surname>Khabbaz</surname><given-names>R.F.</given-names></name>
<name><surname>Armstrong</surname><given-names>L.R.</given-names></name>
<name><surname>Holman</surname><given-names>R.C.</given-names></name>
<name><surname>Bauer</surname><given-names>S.P.</given-names></name>
<name><surname>Graber</surname><given-names>J.</given-names></name>
<name><surname>Strine</surname><given-names>T.</given-names></name>
<name><surname>Miller</surname><given-names>G.</given-names></name>
<name><surname>Reef</surname><given-names>S.</given-names></name>
<name><surname>Tappero</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Hantavirus pulmonary syndrome: The first 100 US cases</article-title><source>J. Infect. Dis.</source><year>1996</year><volume>173</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1093/infdis/173.6.1297</pub-id><pub-id pub-id-type="pmid">8648200</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00198"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clement</surname><given-names>J.</given-names></name>
<name><surname>Heyman</surname><given-names>P.</given-names></name>
<name><surname>McKenna</surname><given-names>P.</given-names></name>
<name><surname>Colson</surname><given-names>P.</given-names></name>
<name><surname>Avsic-Zupanc</surname><given-names>T.</given-names></name>
</person-group><article-title>The hantaviruses of Europe: From the bedside to the bench</article-title><source>Emerg. Infect. Dis.</source><year>1997</year><volume>3</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.3201/eid0302.970218</pub-id><pub-id pub-id-type="pmid">9204306</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00198"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>G.</given-names></name>
</person-group><article-title>Epidemiological progresses of hemorrhagic fever with renal syndrome in China</article-title><source>Chin. Med. J.</source><year>1999</year><volume>112</volume><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">11593522</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00198"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bugert</surname><given-names>J.J.</given-names></name>
<name><surname>Welzel</surname><given-names>T.M.</given-names></name>
<name><surname>Zeier</surname><given-names>M.</given-names></name>
<name><surname>Darai</surname><given-names>G.</given-names></name>
</person-group><article-title>Hantavirus infection--haemorrhagic fever in the Balkans--potential nephrological hazards in the Kosovo war</article-title><source>Nephrol. Dial. Transplant.</source><year>1999</year><volume>14</volume><fpage>1843</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1093/ndt/14.8.1843</pub-id><pub-id pub-id-type="pmid">10462258</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00198"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leitmeyer</surname><given-names>K.</given-names></name>
<name><surname>Sibold</surname><given-names>C.</given-names></name>
<name><surname>Meisel</surname><given-names>H.</given-names></name>
<name><surname>Ulrich</surname><given-names>R.</given-names></name>
<name><surname>Labuda</surname><given-names>M.</given-names></name>
<name><surname>Kruger</surname><given-names>D.H.</given-names></name>
</person-group><article-title>First molecular evidence for Puumala hantavirus in Slovakia</article-title><source>Virus Genes</source><year>2001</year><volume>23</volume><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1023/A:1011840104037</pub-id><pub-id pub-id-type="pmid">11724269</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00198"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vesenjak-Hirjan</surname><given-names>J.</given-names></name>
<name><surname>Punda-Polic</surname><given-names>V.</given-names></name>
<name><surname>Dobe</surname><given-names>M.</given-names></name>
</person-group><article-title>Geographical distribution of arboviruses in Yugoslavia</article-title><source>J. Hyg. Epidemiol. Microbiol. Immunol.</source><year>1991</year><volume>35</volume><fpage>129</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">1658128</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00198"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christova</surname><given-names>I.</given-names></name>
<name><surname>Pishmisheva</surname><given-names>M.</given-names></name>
<name><surname>Trifonova</surname><given-names>I.</given-names></name>
<name><surname>Vatev</surname><given-names>N.</given-names></name>
<name><surname>Stoycheva</surname><given-names>M.</given-names></name>
<name><surname>Tiholova</surname><given-names>M.</given-names></name>
<name><surname>Igova</surname><given-names>D.</given-names></name>
<name><surname>Baev</surname><given-names>M.</given-names></name>
<name><surname>Karagyaurova</surname><given-names>R.</given-names></name>
<name><surname>Prokopova</surname><given-names>U.</given-names></name>
</person-group><article-title>Clinical aspects of hantavirus infections in Bulgaria</article-title><source>Wien. Klin. Wochenschr.</source><year>2017</year><volume>129</volume><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1007/s00508-017-1174-2</pub-id><pub-id pub-id-type="pmid">28229289</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00198"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radosevic</surname><given-names>Z.</given-names></name>
<name><surname>Mohacek</surname><given-names>I.</given-names></name>
</person-group><article-title>The problem of nephropathia epidemica Myhrman-Zetterholm in relation to acute interstitial nephritis</article-title><source>Acta Medica Scand.</source><year>1954</year><volume>149</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1111/j.0954-6820.1954.tb11429.x</pub-id></element-citation></ref><ref id="B29-vaccines-13-00198"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chandy</surname><given-names>S.</given-names></name>
<name><surname>Abraham</surname><given-names>S.</given-names></name>
<name><surname>Sridharan</surname><given-names>G.</given-names></name>
</person-group><article-title>Hantaviruses: An emerging public health threat in India? A review</article-title><source>J. Biosci.</source><year>2008</year><volume>33</volume><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s12038-008-0068-x</pub-id><pub-id pub-id-type="pmid">19208975</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00198"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mustonen</surname><given-names>J.</given-names></name>
<name><surname>Henttonen</surname><given-names>H.</given-names></name>
<name><surname>Vaheri</surname><given-names>A.</given-names></name>
</person-group><article-title>Hantavirus Infections among Military Forces</article-title><source>Mil. Med.</source><year>2024</year><volume>189</volume><fpage>551</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1093/milmed/usad261</pub-id></element-citation></ref><ref id="B31-vaccines-13-00198"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manasia</surname><given-names>M.</given-names></name>
<name><surname>Olinic</surname><given-names>N.</given-names></name>
<name><surname>Zagreanu</surname><given-names>I.</given-names></name>
<name><surname>Serban</surname><given-names>A.</given-names></name>
</person-group><article-title>Hemorrhagic fever with renal syndrome: Report of 11 observations</article-title><source>Int. Urol. Nephrol.</source><year>1977</year><volume>9</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/BF02082021</pub-id><pub-id pub-id-type="pmid">22514</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00198"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>M.</given-names></name>
</person-group><article-title>Occurrence of Epidemic Hemorrhagic Fever in Osaka City: First Cases Found in Japan with Characteristic Feature of Marked Proteinuria</article-title><source>Biken J.</source><year>1964</year><volume>7</volume><fpage>79</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">14290056</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00198"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heyman</surname><given-names>P.</given-names></name>
<name><surname>Vervoort</surname><given-names>T.</given-names></name>
<name><surname>Escutenaire</surname><given-names>S.</given-names></name>
<name><surname>Degrave</surname><given-names>E.</given-names></name>
<name><surname>Konings</surname><given-names>J.</given-names></name>
<name><surname>Vandenvelde</surname><given-names>C.</given-names></name>
<name><surname>Verhagen</surname><given-names>R.</given-names></name>
</person-group><article-title>Incidence of hantavirus infections in Belgium</article-title><source>Virus Res.</source><year>2001</year><volume>77</volume><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S0168-1702(01)00267-2</pub-id><pub-id pub-id-type="pmid">11451489</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00198"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antoniadis</surname><given-names>A.</given-names></name>
<name><surname>Pyrpasopoulos</surname><given-names>M.</given-names></name>
<name><surname>Sion</surname><given-names>M.</given-names></name>
<name><surname>Daniel</surname><given-names>S.</given-names></name>
<name><surname>Peters</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Two cases of hemorrhagic fever with renal syndrome in northern Greece</article-title><source>J. Infect. Dis.</source><year>1984</year><volume>149</volume><fpage>1011</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1093/infdis/149.6.1011</pub-id><pub-id pub-id-type="pmid">6145743</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00198"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eltari</surname><given-names>E.</given-names></name>
<name><surname>Nuti</surname><given-names>M.</given-names></name>
<name><surname>Hasko</surname><given-names>I.</given-names></name>
<name><surname>Gina</surname><given-names>A.</given-names></name>
</person-group><article-title>Haemorrhagic fever with renal syndrome in a case in northern Albania</article-title><source>Lancet</source><year>1987</year><volume>2</volume><fpage>1211</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(87)91348-1</pub-id></element-citation></ref><ref id="B36-vaccines-13-00198"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>Y.C.</given-names></name>
<name><surname>Wong</surname><given-names>T.W.</given-names></name>
<name><surname>Yap</surname><given-names>E.H.</given-names></name>
<name><surname>Tan</surname><given-names>H.C.</given-names></name>
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
<name><surname>Chu</surname><given-names>Y.K.</given-names></name>
<name><surname>Lee</surname><given-names>P.W.</given-names></name>
</person-group><article-title>Haemorrhagic fever with renal syndrome involving the liver</article-title><source>Med. J. Aust.</source><year>1987</year><volume>147</volume><fpage>248</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.1987.tb133422.x</pub-id><pub-id pub-id-type="pmid">2890086</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00198"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suputthamongkol</surname><given-names>Y.</given-names></name>
<name><surname>Nitatpattana</surname><given-names>N.</given-names></name>
<name><surname>Chayakulkeeree</surname><given-names>M.</given-names></name>
<name><surname>Palabodeewat</surname><given-names>S.</given-names></name>
<name><surname>Yoksan</surname><given-names>S.</given-names></name>
<name><surname>Gonzalez</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Hantavirus infection in Thailand: First clinical case report</article-title><source>Southeast Asian J. Trop. Med. Public Health</source><year>2005</year><volume>36</volume><fpage>700</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">16124441</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00198"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonzalez</surname><given-names>J.P.</given-names></name>
<name><surname>Mathiot</surname><given-names>C.C.</given-names></name>
<name><surname>Bouquety</surname><given-names>J.C.</given-names></name>
<name><surname>Diemer</surname><given-names>J.M.</given-names></name>
<name><surname>Guerre</surname><given-names>L.</given-names></name>
<name><surname>Lesbordes</surname><given-names>J.L.</given-names></name>
<name><surname>Madelon</surname><given-names>M.C.</given-names></name>
<name><surname>Georges</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Status of Hantavirus in the Central African Republic</article-title><source>Ann. Inst. Pasteur Virol.</source><year>1988</year><volume>139</volume><fpage>301</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/S0769-2617(88)80044-3</pub-id></element-citation></ref><ref id="B39-vaccines-13-00198"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clement</surname><given-names>J.</given-names></name>
<name><surname>McKenna</surname><given-names>P.</given-names></name>
<name><surname>Colson</surname><given-names>P.</given-names></name>
<name><surname>Damoiseaux</surname><given-names>P.</given-names></name>
<name><surname>Penalba</surname><given-names>C.</given-names></name>
<name><surname>Halin</surname><given-names>P.</given-names></name>
<name><surname>Lombart</surname><given-names>D.</given-names></name>
</person-group><article-title>Hantavirus epidemic in Europe, 1993</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>114</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)90841-9</pub-id><pub-id pub-id-type="pmid">7903742</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00198"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vitarana</surname><given-names>T.</given-names></name>
<name><surname>Colombage</surname><given-names>G.</given-names></name>
<name><surname>Bandaranayake</surname><given-names>V.</given-names></name>
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Hantavirus disease in Sri Lanka</article-title><source>Lancet</source><year>1988</year><volume>2</volume><fpage>1263</fpage></element-citation></ref><ref id="B41-vaccines-13-00198"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobz&#x000ed;k</surname><given-names>J.</given-names></name>
<name><surname>Danes</surname><given-names>L.</given-names></name>
</person-group><article-title>Laboratory-confirmed cases of hemorrhagic fever with renal syndrome which occurred in Breclav 1989-1990</article-title><source>Cesk. Epidemiol. Mikrobiol. Imunol.</source><year>1992</year><volume>41</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">1354571</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00198"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>R.C.</given-names></name>
<name><surname>Sant&#x02019;ana</surname><given-names>M.M.</given-names></name>
<name><surname>Guterres</surname><given-names>A.</given-names></name>
<name><surname>Fernandes</surname><given-names>J.</given-names></name>
<name><surname>Hillesheim</surname><given-names>N.L.</given-names></name>
<name><surname>Lucini</surname><given-names>C.</given-names></name>
<name><surname>Gomes</surname><given-names>R.</given-names></name>
<name><surname>Lamas</surname><given-names>C.</given-names></name>
<name><surname>Bochner</surname><given-names>R.</given-names></name>
<name><surname>Zeccer</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Hantavirus pulmonary syndrome in a highly endemic area of Brazil</article-title><source>Epidemiol. Infect.</source><year>2016</year><volume>144</volume><fpage>1096</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1017/S0950268815002460</pub-id><pub-id pub-id-type="pmid">26464248</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00198"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drebot</surname><given-names>M.A.</given-names></name>
<name><surname>Jones</surname><given-names>S.</given-names></name>
<name><surname>Grolla</surname><given-names>A.</given-names></name>
<name><surname>Safronetz</surname><given-names>D.</given-names></name>
<name><surname>Strong</surname><given-names>J.E.</given-names></name>
<name><surname>Kobinger</surname><given-names>G.</given-names></name>
<name><surname>Lindsay</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Hantavirus pulmonary syndrome in Canada: An overview of clinical features, diagnostics, epidemiology and prevention</article-title><source>Can. Commun. Dis. Rep.</source><year>2015</year><volume>41</volume><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.14745/ccdr.v41i06a02</pub-id><pub-id pub-id-type="pmid">29769944</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00198"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sane</surname><given-names>J.</given-names></name>
<name><surname>Reimerink</surname><given-names>J.</given-names></name>
<name><surname>Harms</surname><given-names>M.</given-names></name>
<name><surname>Bakker</surname><given-names>J.</given-names></name>
<name><surname>Mughini-Gras</surname><given-names>L.</given-names></name>
<name><surname>Schimmer</surname><given-names>B.</given-names></name>
<name><surname>van Pelt</surname><given-names>W.</given-names></name>
</person-group><article-title>Human hantavirus infections in the Netherlands</article-title><source>Emerg. Infect. Dis.</source><year>2014</year><volume>20</volume><fpage>2107</fpage><lpage>2110</lpage><pub-id pub-id-type="doi">10.3201/eid2012.131886</pub-id><pub-id pub-id-type="pmid">25417752</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00198"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bar&#x000f3;</surname><given-names>M.</given-names></name>
<name><surname>Vergara</surname><given-names>J.</given-names></name>
<name><surname>Navarrete</surname><given-names>M.</given-names></name>
</person-group><article-title>Hantavirus in Chile: Review and cases analysis since 1975</article-title><source>Rev. Med. Chil.</source><year>1999</year><volume>127</volume><fpage>1513</fpage><lpage>1523</lpage><pub-id pub-id-type="doi">10.4067/S0034-98871999001200015</pub-id><pub-id pub-id-type="pmid">10835761</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00198"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pini</surname><given-names>N.</given-names></name>
</person-group><article-title>Hantavirus pulmonary syndrome in Latin America</article-title><source>Curr. Opin. Infect. Dis.</source><year>2004</year><volume>17</volume><fpage>427</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1097/00001432-200410000-00007</pub-id><pub-id pub-id-type="pmid">15353962</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00198"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Figueiredo</surname><given-names>L.T.</given-names></name>
<name><surname>Souza</surname><given-names>W.M.</given-names></name>
<name><surname>Ferres</surname><given-names>M.</given-names></name>
<name><surname>Enria</surname><given-names>D.A.</given-names></name>
</person-group><article-title>Hantaviruses and cardiopulmonary syndrome in South America</article-title><source>Virus Res.</source><year>2014</year><volume>187</volume><fpage>43</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.01.015</pub-id><pub-id pub-id-type="pmid">24508343</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00198"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chan</surname><given-names>K.P.</given-names></name>
<name><surname>Chan</surname><given-names>Y.C.</given-names></name>
<name><surname>Doraisingham</surname><given-names>S.</given-names></name>
</person-group><article-title>A severe case of hemorrhagic fever with renal syndrome in Singapore</article-title><source>Southeast Asian J. Trop. Med. Public Health</source><year>1996</year><volume>27</volume><fpage>408</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">9280013</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00198"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pejcoch</surname><given-names>M.</given-names></name>
<name><surname>Kriz</surname><given-names>B.</given-names></name>
</person-group><article-title>Hantaviruses in the Czech Republic</article-title><source>Emerg. Infect. Dis.</source><year>2003</year><volume>9</volume><fpage>756</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.3201/eid0906.020772</pub-id><pub-id pub-id-type="pmid">12781027</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00198"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vincent</surname><given-names>M.J.</given-names></name>
<name><surname>Quiroz</surname><given-names>E.</given-names></name>
<name><surname>Gracia</surname><given-names>F.</given-names></name>
<name><surname>Sanchez</surname><given-names>A.J.</given-names></name>
<name><surname>Ksiazek</surname><given-names>T.G.</given-names></name>
<name><surname>Kitsutani</surname><given-names>P.T.</given-names></name>
<name><surname>Ruedas</surname><given-names>L.A.</given-names></name>
<name><surname>Tinnin</surname><given-names>D.S.</given-names></name>
<name><surname>Caceres</surname><given-names>L.</given-names></name>
<name><surname>Garcia</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Hantavirus pulmonary syndrome in Panama: Identification of novel hantaviruses and their likely reservoirs</article-title><source>Virology</source><year>2000</year><volume>277</volume><fpage>14</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1006/viro.2000.0563</pub-id><pub-id pub-id-type="pmid">11062031</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00198"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Groen</surname><given-names>J.</given-names></name>
<name><surname>Koraka</surname><given-names>P.</given-names></name>
<name><surname>Edwards</surname><given-names>C.N.</given-names></name>
<name><surname>Branch</surname><given-names>S.L.</given-names></name>
<name><surname>Douglas</surname><given-names>K.O.</given-names></name>
<name><surname>Osterhaus</surname><given-names>A.D.</given-names></name>
<name><surname>Levett</surname><given-names>P.N.</given-names></name>
</person-group><article-title>Serological evidence of hantavirus in humans and rodents in Barbados</article-title><source>J. Infect.</source><year>2002</year><volume>45</volume><fpage>109</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1053/jinf.2002.1028</pub-id><pub-id pub-id-type="pmid">12217714</pub-id>
</element-citation></ref><ref id="B52-vaccines-13-00198"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosasih</surname><given-names>H.</given-names></name>
<name><surname>Ibrahim</surname><given-names>I.N.</given-names></name>
<name><surname>Wicaksana</surname><given-names>R.</given-names></name>
<name><surname>Alisjahbana</surname><given-names>B.</given-names></name>
<name><surname>Hoo</surname><given-names>Y.</given-names></name>
<name><surname>Yo</surname><given-names>I.H.</given-names></name>
<name><surname>Antonjaya</surname><given-names>U.</given-names></name>
<name><surname>Widjaja</surname><given-names>S.</given-names></name>
<name><surname>Winoto</surname><given-names>I.</given-names></name>
<name><surname>Williams</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Evidence of human hantavirus infection and zoonotic investigation of hantavirus prevalence in rodents in western Java, Indonesia</article-title><source>Vector Borne Zoonotic Dis.</source><year>2011</year><volume>11</volume><fpage>709</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1089/vbz.2010.0093</pub-id><pub-id pub-id-type="pmid">21142967</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00198"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>F.</given-names></name>
<name><surname>Mossong</surname><given-names>J.</given-names></name>
</person-group><article-title>Increased hantavirus infections in Luxembourg, August 2005</article-title><source>Eurosurveillance</source><year>2005</year><volume>10</volume><fpage>2781</fpage><pub-id pub-id-type="doi">10.2807/esw.10.34.02781-en</pub-id></element-citation></ref><ref id="B54-vaccines-13-00198"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knap</surname><given-names>J.P.</given-names></name>
<name><surname>Trybusz</surname><given-names>A.</given-names></name>
</person-group><article-title>Haemorrhagic fever with renal syndrome (HFRS)--Hantavirus infection disease appearing in Poland</article-title><source>Pol. Merkur. Lek.</source><year>2006</year><volume>21</volume><fpage>411</fpage><lpage>417</lpage></element-citation></ref><ref id="B55-vaccines-13-00198"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montoya-Ruiz</surname><given-names>C.</given-names></name>
<name><surname>Diaz</surname><given-names>F.J.</given-names></name>
<name><surname>Rodas</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Recent evidence of hantavirus circulation in the American tropic</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>1274</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.3390/v6031274</pub-id><pub-id pub-id-type="pmid">24638203</pub-id>
</element-citation></ref><ref id="B56-vaccines-13-00198"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuchuloria</surname><given-names>T.</given-names></name>
<name><surname>Clark</surname><given-names>D.V.</given-names></name>
<name><surname>Hepburn</surname><given-names>M.J.</given-names></name>
<name><surname>Tsertsvadze</surname><given-names>T.</given-names></name>
<name><surname>Pimentel</surname><given-names>G.</given-names></name>
<name><surname>Imnadze</surname><given-names>P.</given-names></name>
</person-group><article-title>Hantavirus infection in the Republic of Georgia</article-title><source>Emerg. Infect. Dis.</source><year>2009</year><volume>15</volume><fpage>1489</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.3201/eid1509.090617</pub-id><pub-id pub-id-type="pmid">19788822</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00198"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fontana-Binard</surname><given-names>L.</given-names></name>
<name><surname>Schultze</surname><given-names>D.</given-names></name>
<name><surname>Rojanavisut</surname><given-names>B.S.</given-names></name>
<name><surname>Kruger</surname><given-names>D.H.</given-names></name>
<name><surname>Dollenmaier</surname><given-names>G.</given-names></name>
<name><surname>Zanetti</surname><given-names>G.</given-names></name>
<name><surname>Meylan</surname><given-names>P.</given-names></name>
</person-group><article-title>First case of nephropathia epidemica acquired in Switzerland</article-title><source>Rev. Med. Suisse</source><year>2008</year><volume>4</volume><fpage>1572</fpage><lpage>1575</lpage><pub-id pub-id-type="pmid">18672548</pub-id>
</element-citation></ref><ref id="B58-vaccines-13-00198"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Celebi</surname><given-names>G.</given-names></name>
<name><surname>Oztoprak</surname><given-names>N.</given-names></name>
<name><surname>Oktem</surname><given-names>I.M.A.</given-names></name>
<name><surname>Heyman</surname><given-names>P.</given-names></name>
<name><surname>Lundkvist</surname><given-names>A.</given-names></name>
<name><surname>Wahlstrom</surname><given-names>M.</given-names></name>
<name><surname>Kokturk</surname><given-names>F.</given-names></name>
<name><surname>Piskin</surname><given-names>N.</given-names></name>
</person-group><article-title>Dynamics of Puumala hantavirus outbreak in Black Sea Region, Turkey</article-title><source>Zoonoses Public Health</source><year>2019</year><volume>66</volume><fpage>783</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1111/zph.12625</pub-id><pub-id pub-id-type="pmid">31293096</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00198"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Depaulis</surname><given-names>A.</given-names></name>
<name><surname>Morgan</surname><given-names>M.M.</given-names></name>
<name><surname>Liebeskind</surname><given-names>J.C.</given-names></name>
</person-group><article-title>GABAergic modulation of the analgesic effects of morphine microinjected in the ventral periaqueductal gray matter of the rat</article-title><source>Brain Res.</source><year>1987</year><volume>436</volume><fpage>223</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(87)91665-9</pub-id><pub-id pub-id-type="pmid">3435824</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00198"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salehi-Vaziri</surname><given-names>M.</given-names></name>
<name><surname>Kaleji</surname><given-names>A.S.</given-names></name>
<name><surname>Fazlalipour</surname><given-names>M.</given-names></name>
<name><surname>Jalali</surname><given-names>T.</given-names></name>
<name><surname>Mohammadi</surname><given-names>T.</given-names></name>
<name><surname>Khakifirouz</surname><given-names>S.</given-names></name>
<name><surname>Baniasadi</surname><given-names>V.</given-names></name>
<name><surname>Pouriayevali</surname><given-names>M.H.</given-names></name>
<name><surname>Mahmoudi</surname><given-names>A.</given-names></name>
<name><surname>Tordo</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Hantavirus infection in Iranian patients suspected to viral hemorrhagic fever</article-title><source>J. Med. Virol.</source><year>2019</year><volume>91</volume><fpage>1737</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1002/jmv.25522</pub-id><pub-id pub-id-type="pmid">31218696</pub-id>
</element-citation></ref><ref id="B61-vaccines-13-00198"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mattar</surname><given-names>S.</given-names></name>
<name><surname>Garzon</surname><given-names>D.</given-names></name>
<name><surname>Tadeu</surname><given-names>L.</given-names></name>
<name><surname>Faccini-Martinez</surname><given-names>A.A.</given-names></name>
<name><surname>Mills</surname><given-names>J.N.</given-names></name>
</person-group><article-title>Serological diagnosis of hantavirus pulmonary syndrome in a febrile patient in Colombia</article-title><source>Int. J. Infect. Dis.</source><year>2014</year><volume>25</volume><fpage>201</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2014.03.1396</pub-id><pub-id pub-id-type="pmid">24970702</pub-id>
</element-citation></ref><ref id="B62-vaccines-13-00198"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chau</surname><given-names>R.</given-names></name>
<name><surname>Bhatt</surname><given-names>N.</given-names></name>
<name><surname>Manhi&#x000e7;a</surname><given-names>I.</given-names></name>
<name><surname>C&#x000e2;ndido</surname><given-names>S.</given-names></name>
<name><surname>de Deus</surname><given-names>N.</given-names></name>
<name><surname>Guiliche</surname><given-names>O.</given-names></name>
<name><surname>Tivane</surname><given-names>A.</given-names></name>
<name><surname>Evaristo</surname><given-names>L.V.</given-names></name>
<name><surname>Guterres</surname><given-names>A.</given-names></name>
<name><surname>Monteiro</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>First serological evidence of hantavirus among febrile patients in Mozambique</article-title><source>Int. J. Infect. Dis.</source><year>2017</year><volume>61</volume><fpage>51</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2017.06.001</pub-id><pub-id pub-id-type="pmid">28602764</pub-id>
</element-citation></ref><ref id="B63-vaccines-13-00198"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>C.N.</given-names></name>
<name><surname>Blacksell</surname><given-names>S.D.</given-names></name>
<name><surname>Paris</surname><given-names>D.H.</given-names></name>
<name><surname>Arjyal</surname><given-names>A.</given-names></name>
<name><surname>Karkey</surname><given-names>A.</given-names></name>
<name><surname>Dongol</surname><given-names>S.</given-names></name>
<name><surname>Giri</surname><given-names>A.</given-names></name>
<name><surname>Dolecek</surname><given-names>C.</given-names></name>
<name><surname>Day</surname><given-names>N.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Undifferentiated febrile illness in Kathmandu, Nepal</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2015</year><volume>92</volume><fpage>875</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.14-0709</pub-id><pub-id pub-id-type="pmid">25667056</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00198"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moolla</surname><given-names>N.</given-names></name>
<name><surname>Adler</surname><given-names>D.</given-names></name>
<name><surname>Blumberg</surname><given-names>L.</given-names></name>
<name><surname>Glass</surname><given-names>A.</given-names></name>
<name><surname>Grobbelaar</surname><given-names>A.</given-names></name>
<name><surname>Le Roux</surname><given-names>C.</given-names></name>
<name><surname>Paweska</surname><given-names>J.</given-names></name>
<name><surname>Weyer</surname><given-names>J.</given-names></name>
</person-group><article-title>First report of an imported case of haemorrhagic fever with renal syndrome in South Africa</article-title><source>S. Afr. Med. J.</source><year>2022</year><volume>112</volume><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.7196/SAMJ.2022.v112i8.16540</pub-id><pub-id pub-id-type="pmid">36214393</pub-id>
</element-citation></ref><ref id="B65-vaccines-13-00198"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kolben</surname><given-names>Y.</given-names></name>
<name><surname>Azmanov</surname><given-names>H.</given-names></name>
<name><surname>Ishay</surname><given-names>Y.</given-names></name>
<name><surname>Orenbuch-Harroch</surname><given-names>E.</given-names></name>
<name><surname>Milgrom</surname><given-names>Y.</given-names></name>
</person-group><article-title>Hemorrhagic Fever with Renal Syndrome Caused by Hantavirus Infection: First Reported Case in Israel</article-title><source>Isr. Med. Assoc. J.</source><year>2022</year><volume>24</volume><fpage>621</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">36168171</pub-id>
</element-citation></ref><ref id="B66-vaccines-13-00198"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jakab</surname><given-names>F.</given-names></name>
<name><surname>Sebok</surname><given-names>J.</given-names></name>
<name><surname>Ferenczi</surname><given-names>E.</given-names></name>
<name><surname>Horvath</surname><given-names>G.</given-names></name>
<name><surname>Szucs</surname><given-names>G.</given-names></name>
</person-group><article-title>First detection of Dobrava hantavirus from a patient with severe haemorrhagic fever with renal syndrome by SYBR Green-based real time RT-PCR</article-title><source>Scand. J. Infect. Dis.</source><year>2007</year><volume>39</volume><fpage>902</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1080/00365540701387072</pub-id><pub-id pub-id-type="pmid">17852891</pub-id>
</element-citation></ref><ref id="B67-vaccines-13-00198"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>N.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Niu</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Ye</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Risk of hemorrhagic fever with renal syndrome associated with meteorological factors in diverse epidemic regions: A nationwide longitudinal study in China</article-title><source>Infect. Dis. Poverty</source><year>2025</year><volume>14</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s40249-024-01272-7</pub-id><pub-id pub-id-type="pmid">39815365</pub-id>
</element-citation></ref><ref id="B68-vaccines-13-00198"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Gao</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Chang</surname><given-names>N.</given-names></name>
<name><surname>Tao</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Spatiotemporal trends of hemorrhagic fever with renal syndrome (HFRS) in China under climate variation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2024</year><volume>121</volume><fpage>e2312556121</fpage><pub-id pub-id-type="doi">10.1073/pnas.2312556121</pub-id><pub-id pub-id-type="pmid">38227655</pub-id>
</element-citation></ref><ref id="B69-vaccines-13-00198"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guterres</surname><given-names>A.</given-names></name>
<name><surname>de Lemos</surname><given-names>E.R.S.</given-names></name>
</person-group><article-title>Hantaviruses and a neglected environmental determinant</article-title><source>One Health</source><year>2018</year><volume>5</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.onehlt.2017.12.002</pub-id><pub-id pub-id-type="pmid">29911161</pub-id>
</element-citation></ref><ref id="B70-vaccines-13-00198"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duggan</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Prevalence of Seoul hantavirus in UK wild rats: An emerging public health problem?</article-title><source>Vet. Rec.</source><year>2019</year><volume>184</volume><fpage>523</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1136/vr.l1163</pub-id><pub-id pub-id-type="pmid">31023948</pub-id>
</element-citation></ref><ref id="B71-vaccines-13-00198"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
<name><surname>Josleyn</surname><given-names>M.</given-names></name>
<name><surname>Ballantyne</surname><given-names>J.</given-names></name>
<name><surname>Brocato</surname><given-names>R.</given-names></name>
</person-group><article-title>A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS)</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>4314</fpage><lpage>4321</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.025</pub-id><pub-id pub-id-type="pmid">23892100</pub-id>
</element-citation></ref><ref id="B72-vaccines-13-00198"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kariwa</surname><given-names>H.</given-names></name>
<name><surname>Yoshimatsu</surname><given-names>K.</given-names></name>
<name><surname>Arikawa</surname><given-names>J.</given-names></name>
</person-group><article-title>Hantavirus infection in East Asia</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2007</year><volume>30</volume><fpage>341</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2007.05.011</pub-id><pub-id pub-id-type="pmid">17655929</pub-id>
</element-citation></ref><ref id="B73-vaccines-13-00198"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jonsson</surname><given-names>C.B.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Replication of hantaviruses</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2001</year><volume>256</volume><fpage>15</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-56753-7_2</pub-id><pub-id pub-id-type="pmid">11217402</pub-id>
</element-citation></ref><ref id="B74-vaccines-13-00198"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Graham</surname><given-names>B.S.</given-names></name>
<name><surname>Gilman</surname><given-names>M.S.A.</given-names></name>
<name><surname>McLellan</surname><given-names>J.S.</given-names></name>
</person-group><article-title>Structure-Based Vaccine Antigen Design</article-title><source>Annu. Rev. Med.</source><year>2019</year><volume>70</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-121217-094234</pub-id><pub-id pub-id-type="pmid">30691364</pub-id>
</element-citation></ref><ref id="B75-vaccines-13-00198"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muyangwa</surname><given-names>M.</given-names></name>
<name><surname>Martynova</surname><given-names>E.V.</given-names></name>
<name><surname>Khaiboullina</surname><given-names>S.F.</given-names></name>
<name><surname>Morzunov</surname><given-names>S.P.</given-names></name>
<name><surname>Rizvanov</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Hantaviral Proteins: Structure, Functions, and Role in Hantavirus Infection</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><elocation-id>1326</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2015.01326</pub-id><pub-id pub-id-type="pmid">26640463</pub-id>
</element-citation></ref><ref id="B76-vaccines-13-00198"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rizvanov</surname><given-names>A.A.</given-names></name>
<name><surname>Khaiboullina</surname><given-names>S.F.</given-names></name>
<name><surname>St Jeor</surname><given-names>S.</given-names></name>
</person-group><article-title>Development of reassortant viruses between pathogenic hantavirus strains</article-title><source>Virology</source><year>2004</year><volume>327</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2004.07.012</pub-id><pub-id pub-id-type="pmid">15351210</pub-id>
</element-citation></ref><ref id="B77-vaccines-13-00198"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brocato</surname><given-names>R.</given-names></name>
<name><surname>Josleyn</surname><given-names>M.</given-names></name>
<name><surname>Ballantyne</surname><given-names>J.</given-names></name>
<name><surname>Vial</surname><given-names>P.</given-names></name>
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
</person-group><article-title>DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e35996</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035996</pub-id><pub-id pub-id-type="pmid">22558299</pub-id>
</element-citation></ref><ref id="B78-vaccines-13-00198"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klingstrom</surname><given-names>J.</given-names></name>
<name><surname>Stoltz</surname><given-names>M.</given-names></name>
<name><surname>Hardestam</surname><given-names>J.</given-names></name>
<name><surname>Ahlm</surname><given-names>C.</given-names></name>
<name><surname>Lundkvist</surname><given-names>A.</given-names></name>
</person-group><article-title>Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge</article-title><source>Antivir. Ther.</source><year>2008</year><volume>13</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1177/135965350801300114</pub-id><pub-id pub-id-type="pmid">18389907</pub-id>
</element-citation></ref><ref id="B79-vaccines-13-00198"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Wei</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>S.</given-names></name>
</person-group><article-title>The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: Potential application for immunotherapy and passive immunization</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2002</year><volume>298</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)02491-9</pub-id><pub-id pub-id-type="pmid">12408987</pub-id>
</element-citation></ref><ref id="B80-vaccines-13-00198"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khaiboullina</surname><given-names>S.F.</given-names></name>
<name><surname>St Jeor</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Hantavirus immunology</article-title><source>Viral Immunol.</source><year>2002</year><volume>15</volume><fpage>609</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1089/088282402320914548</pub-id><pub-id pub-id-type="pmid">12513931</pub-id>
</element-citation></ref><ref id="B81-vaccines-13-00198"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duehr</surname><given-names>J.</given-names></name>
<name><surname>McMahon</surname><given-names>M.</given-names></name>
<name><surname>Williamson</surname><given-names>B.</given-names></name>
<name><surname>Amanat</surname><given-names>F.</given-names></name>
<name><surname>Durbin</surname><given-names>A.</given-names></name>
<name><surname>Hawman</surname><given-names>D.W.</given-names></name>
<name><surname>Noack</surname><given-names>D.</given-names></name>
<name><surname>Uhl</surname><given-names>S.</given-names></name>
<name><surname>Tan</surname><given-names>G.S.</given-names></name>
<name><surname>Feldmann</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model</article-title><source>mBio</source><year>2020</year><volume>11</volume><fpage>e00028-20</fpage><pub-id pub-id-type="doi">10.1128/mBio.00028-20</pub-id><pub-id pub-id-type="pmid">32209676</pub-id>
</element-citation></ref><ref id="B82-vaccines-13-00198"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maes</surname><given-names>P.</given-names></name>
<name><surname>Clement</surname><given-names>J.</given-names></name>
<name><surname>Van Ranst</surname><given-names>M.</given-names></name>
</person-group><article-title>Recent approaches in hantavirus vaccine development</article-title><source>Expert Rev. Vaccines</source><year>2009</year><volume>8</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1586/14760584.8.1.67</pub-id><pub-id pub-id-type="pmid">19093774</pub-id>
</element-citation></ref><ref id="B83-vaccines-13-00198"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tischler</surname><given-names>N.D.</given-names></name>
<name><surname>Gonzalez</surname><given-names>A.</given-names></name>
<name><surname>Perez-Acle</surname><given-names>T.</given-names></name>
<name><surname>Rosemblatt</surname><given-names>M.</given-names></name>
<name><surname>Valenzuela</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Hantavirus Gc glycoprotein: Evidence for a class II fusion protein</article-title><source>J. Gen. Virol.</source><year>2005</year><volume>86</volume><fpage>2937</fpage><lpage>2947</lpage><pub-id pub-id-type="doi">10.1099/vir.0.81083-0</pub-id><pub-id pub-id-type="pmid">16227214</pub-id>
</element-citation></ref><ref id="B84-vaccines-13-00198"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asada</surname><given-names>H.</given-names></name>
<name><surname>Tamura</surname><given-names>M.</given-names></name>
<name><surname>Kondo</surname><given-names>K.</given-names></name>
<name><surname>Okuno</surname><given-names>Y.</given-names></name>
<name><surname>Takahashi</surname><given-names>Y.</given-names></name>
<name><surname>Dohi</surname><given-names>Y.</given-names></name>
<name><surname>Nagai</surname><given-names>T.</given-names></name>
<name><surname>Kurata</surname><given-names>T.</given-names></name>
<name><surname>Yamanishi</surname><given-names>K.</given-names></name>
</person-group><article-title>Role of T lymphocyte subsets in protection and recovery from Hantaan virus infection in mice</article-title><source>J. Gen. Virol.</source><year>1987</year><volume>68</volume><issue-part>Pt 7</issue-part><fpage>1961</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-68-7-1961</pub-id><pub-id pub-id-type="pmid">2885394</pub-id>
</element-citation></ref><ref id="B85-vaccines-13-00198"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Tang</surname><given-names>K.</given-names></name>
<name><surname>Zhuang</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/K(b) Transgenic Mice</article-title><source>Front. Immunol.</source><year>2016</year><volume>7</volume><elocation-id>298</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2016.00298</pub-id><pub-id pub-id-type="pmid">27551282</pub-id>
</element-citation></ref><ref id="B86-vaccines-13-00198"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tischler</surname><given-names>N.D.</given-names></name>
<name><surname>Rosemblatt</surname><given-names>M.</given-names></name>
<name><surname>Valenzuela</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Characterization of cross-reactive and serotype-specific epitopes on the nucleocapsid proteins of hantaviruses</article-title><source>Virus Res.</source><year>2008</year><volume>135</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2008.01.013</pub-id><pub-id pub-id-type="pmid">18342973</pub-id>
</element-citation></ref><ref id="B87-vaccines-13-00198"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoshimatsu</surname><given-names>K.</given-names></name>
<name><surname>Yoo</surname><given-names>Y.C.</given-names></name>
<name><surname>Yoshida</surname><given-names>R.</given-names></name>
<name><surname>Ishihara</surname><given-names>C.</given-names></name>
<name><surname>Azuma</surname><given-names>I.</given-names></name>
<name><surname>Arikawa</surname><given-names>J.</given-names></name>
</person-group><article-title>Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins</article-title><source>Arch. Virol.</source><year>1993</year><volume>130</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/BF01309667</pub-id><pub-id pub-id-type="pmid">8517793</pub-id>
</element-citation></ref><ref id="B88-vaccines-13-00198"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khaiboullina</surname><given-names>S.F.</given-names></name>
<name><surname>Morzunov</surname><given-names>S.P.</given-names></name>
<name><surname>St Jeor</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Hantaviruses: Molecular biology, evolution and pathogenesis</article-title><source>Curr. Mol. Med.</source><year>2005</year><volume>5</volume><fpage>773</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.2174/156652405774962317</pub-id><pub-id pub-id-type="pmid">16375712</pub-id>
</element-citation></ref><ref id="B89-vaccines-13-00198"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lundkvist</surname><given-names>A.</given-names></name>
<name><surname>Horling</surname><given-names>J.</given-names></name>
<name><surname>Athlin</surname><given-names>L.</given-names></name>
<name><surname>Rosen</surname><given-names>A.</given-names></name>
<name><surname>Niklasson</surname><given-names>B.</given-names></name>
</person-group><article-title>Neutralizing human monoclonal antibodies against Puumala virus, causative agent of nephropathia epidemica: A novel method using antigen-coated magnetic beads for specific B cell isolation</article-title><source>J. Gen. Virol.</source><year>1993</year><volume>74</volume><issue-part>Pt 7</issue-part><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-74-7-1303</pub-id><pub-id pub-id-type="pmid">7687648</pub-id>
</element-citation></ref><ref id="B90-vaccines-13-00198"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
<name><surname>van der Groen</surname><given-names>G.</given-names></name>
</person-group><article-title>Hemorrhagic fever with renal syndrome</article-title><source>Prog. Med. Virol. Fortschritte Der Med. Virusforsch. Prog. En Virol. Medicale</source><year>1989</year><volume>36</volume><fpage>62</fpage><lpage>102</lpage></element-citation></ref><ref id="B91-vaccines-13-00198"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avsic-Zupanc</surname><given-names>T.</given-names></name>
<name><surname>Saksida</surname><given-names>A.</given-names></name>
<name><surname>Korva</surname><given-names>M.</given-names></name>
</person-group><article-title>Hantavirus infections</article-title><source>Clin. Microbiol. Infect.</source><year>2019</year><volume>21</volume><fpage>e6</fpage><lpage>e16</lpage><pub-id pub-id-type="doi">10.1111/1469-0691.12291</pub-id></element-citation></ref><ref id="B92-vaccines-13-00198"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kilpatrick</surname><given-names>E.D.</given-names></name>
<name><surname>Terajima</surname><given-names>M.</given-names></name>
<name><surname>Koster</surname><given-names>F.T.</given-names></name>
<name><surname>Catalina</surname><given-names>M.D.</given-names></name>
<name><surname>Cruz</surname><given-names>J.</given-names></name>
<name><surname>Ennis</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>3297</fpage><lpage>3304</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.5.3297</pub-id><pub-id pub-id-type="pmid">14978138</pub-id>
</element-citation></ref><ref id="B93-vaccines-13-00198"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van Epps</surname><given-names>H.L.</given-names></name>
<name><surname>Terajima</surname><given-names>M.</given-names></name>
<name><surname>Mustonen</surname><given-names>J.</given-names></name>
<name><surname>Arstila</surname><given-names>T.P.</given-names></name>
<name><surname>Corey</surname><given-names>E.A.</given-names></name>
<name><surname>Vaheri</surname><given-names>A.</given-names></name>
<name><surname>Ennis</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Long-lived memory T lymphocyte responses after hantavirus infection</article-title><source>J. Exp. Med.</source><year>2002</year><volume>196</volume><fpage>579</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1084/jem.20011255</pub-id><pub-id pub-id-type="pmid">12208874</pub-id>
</element-citation></ref><ref id="B94-vaccines-13-00198"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manigold</surname><given-names>T.</given-names></name>
<name><surname>Mori</surname><given-names>A.</given-names></name>
<name><surname>Graumann</surname><given-names>R.</given-names></name>
<name><surname>Llop</surname><given-names>E.</given-names></name>
<name><surname>Simon</surname><given-names>V.</given-names></name>
<name><surname>Ferres</surname><given-names>M.</given-names></name>
<name><surname>Valdivieso</surname><given-names>F.</given-names></name>
<name><surname>Castillo</surname><given-names>C.</given-names></name>
<name><surname>Hjelle</surname><given-names>B.</given-names></name>
<name><surname>Vial</surname><given-names>P.</given-names></name>
</person-group><article-title>Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><elocation-id>e1000779</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000779</pub-id><pub-id pub-id-type="pmid">20174562</pub-id>
</element-citation></ref><ref id="B95-vaccines-13-00198"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Braun</surname><given-names>M.</given-names></name>
<name><surname>Tischler</surname><given-names>N.D.</given-names></name>
<name><surname>Stoltz</surname><given-names>M.</given-names></name>
<name><surname>Sundstrom</surname><given-names>K.B.</given-names></name>
<name><surname>Bjorkstrom</surname><given-names>N.K.</given-names></name>
<name><surname>Ljunggren</surname><given-names>H.G.</given-names></name>
<name><surname>Klingstrom</surname><given-names>J.</given-names></name>
</person-group><article-title>Hantavirus-infection confers resistance to cytotoxic lymphocyte-mediated apoptosis</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003272</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003272</pub-id><pub-id pub-id-type="pmid">23555267</pub-id>
</element-citation></ref><ref id="B96-vaccines-13-00198"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borges</surname><given-names>A.A.</given-names></name>
<name><surname>Campos</surname><given-names>G.M.</given-names></name>
<name><surname>Moreli</surname><given-names>M.L.</given-names></name>
<name><surname>Moro Souza</surname><given-names>R.L.</given-names></name>
<name><surname>Saggioro</surname><given-names>F.P.</given-names></name>
<name><surname>Figueiredo</surname><given-names>G.G.</given-names></name>
<name><surname>Livonesi</surname><given-names>M.C.</given-names></name>
<name><surname>Moraes Figueiredo</surname><given-names>L.T.</given-names></name>
</person-group><article-title>Role of mixed Th1 and Th2 serum cytokines on pathogenesis and prognosis of hantavirus pulmonary syndrome</article-title><source>Microbes Infect.</source><year>2008</year><volume>10</volume><fpage>1150</fpage><lpage>1157</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2008.06.006</pub-id><pub-id pub-id-type="pmid">18606242</pub-id>
</element-citation></ref><ref id="B97-vaccines-13-00198"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Easterbrook</surname><given-names>J.D.</given-names></name>
<name><surname>Zink</surname><given-names>M.C.</given-names></name>
<name><surname>Klein</surname><given-names>S.L.</given-names></name>
</person-group><article-title>Regulatory T cells enhance persistence of the zoonotic pathogen Seoul virus in its reservoir host</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>15502</fpage><lpage>15507</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707453104</pub-id><pub-id pub-id-type="pmid">17878294</pub-id>
</element-citation></ref><ref id="B98-vaccines-13-00198"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>H.W.</given-names></name>
<name><surname>Howard</surname><given-names>C.R.</given-names></name>
</person-group><article-title>Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax)</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>2569</fpage><lpage>2575</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00057-2</pub-id><pub-id pub-id-type="pmid">10418904</pub-id>
</element-citation></ref><ref id="B99-vaccines-13-00198"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>H.W.</given-names></name>
<name><surname>Howard</surname><given-names>C.R.</given-names></name>
<name><surname>Lee</surname><given-names>H.W.</given-names></name>
</person-group><article-title>Review of an inactivated vaccine against hantaviruses</article-title><source>Intervirology</source><year>2002</year><volume>45</volume><fpage>328</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1159/000067925</pub-id><pub-id pub-id-type="pmid">12602351</pub-id>
</element-citation></ref><ref id="B100-vaccines-13-00198"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>J.W.</given-names></name>
<name><surname>Moon</surname><given-names>S.S.</given-names></name>
<name><surname>Gu</surname><given-names>S.H.</given-names></name>
<name><surname>Song</surname><given-names>K.J.</given-names></name>
<name><surname>Baek</surname><given-names>L.J.</given-names></name>
<name><surname>Kim</surname><given-names>H.C.</given-names></name>
<name><surname>Kijek</surname><given-names>T.</given-names></name>
<name><surname>O&#x02019;Guinn</surname><given-names>M.L.</given-names></name>
<name><surname>Lee</surname><given-names>J.S.</given-names></name>
<name><surname>Turell</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Hemorrhagic fever with renal syndrome in 4 US soldiers, South Korea, 2005</article-title><source>Emerg. Infect. Dis.</source><year>2009</year><volume>15</volume><fpage>1833</fpage><lpage>1836</lpage><pub-id pub-id-type="doi">10.3201/eid1511.090076</pub-id><pub-id pub-id-type="pmid">19891878</pub-id>
</element-citation></ref><ref id="B101-vaccines-13-00198"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yi</surname><given-names>Y.</given-names></name>
<name><surname>Park</surname><given-names>H.</given-names></name>
<name><surname>Jung</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome</article-title><source>Kidney Res. Clin. Pract.</source><year>2018</year><volume>37</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.23876/j.krcp.18.0044</pub-id><pub-id pub-id-type="pmid">30619692</pub-id>
</element-citation></ref><ref id="B102-vaccines-13-00198"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>Y.K.</given-names></name>
<name><surname>Gligic</surname><given-names>A.</given-names></name>
<name><surname>Tomanovic</surname><given-names>S.</given-names></name>
<name><surname>Bozovjc</surname><given-names>B.</given-names></name>
<name><surname>Obradovic</surname><given-names>M.</given-names></name>
<name><surname>Woo</surname><given-names>Y.D.</given-names></name>
<name><surname>An</surname><given-names>C.N.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.S.</given-names></name>
<name><surname>Park</surname><given-names>S.C.</given-names></name>
</person-group><article-title>A Field Efficacy Trial of Inactivated Hantaan Virus Vaccine (Hantavax(TM)) Against Hemorrhagic Fever with Renal Syndrome (HFRS) in the Endemic Areas of Yugoslavia from 1996 to 1998</article-title><source>J. Korean Soc. Virol.</source><year>1999</year><volume>29</volume><fpage>55</fpage><lpage>64</lpage></element-citation></ref><ref id="B103-vaccines-13-00198"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sohn</surname><given-names>Y.M.</given-names></name>
<name><surname>Rho</surname><given-names>H.O.</given-names></name>
<name><surname>Park</surname><given-names>M.S.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
<name><surname>Summers</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): Consideration of active immunization in South Korea</article-title><source>Yonsei Med. J.</source><year>2001</year><volume>42</volume><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.3349/ymj.2001.42.3.278</pub-id><pub-id pub-id-type="pmid">11456392</pub-id>
</element-citation></ref><ref id="B104-vaccines-13-00198"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>J.</given-names></name>
<name><surname>Ko</surname><given-names>S.J.</given-names></name>
<name><surname>Oh</surname><given-names>H.S.</given-names></name>
<name><surname>Moon</surname><given-names>S.M.</given-names></name>
<name><surname>Song</surname><given-names>J.W.</given-names></name>
<name><surname>Huh</surname><given-names>K.</given-names></name>
</person-group><article-title>Protective Effectiveness of Inactivated Hantavirus Vaccine Against Hemorrhagic Fever With Renal Syndrome</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>217</volume><fpage>1417</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy037</pub-id><pub-id pub-id-type="pmid">29373686</pub-id>
</element-citation></ref><ref id="B105-vaccines-13-00198"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bae</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Introduction of Vaccinomics to Develop Personalized Vaccines in Light of Changes in the Usage of Hantaan Virus Vaccine (Hantavax(R)) in Korea</article-title><source>J. Prev. Med. Public Health</source><year>2019</year><volume>52</volume><fpage>277</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.3961/jpmph.19.018</pub-id><pub-id pub-id-type="pmid">31588696</pub-id>
</element-citation></ref><ref id="B106-vaccines-13-00198"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>J.Y.</given-names></name>
<name><surname>Jeong</surname><given-names>H.W.</given-names></name>
<name><surname>Yun</surname><given-names>J.W.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Woo</surname><given-names>H.J.</given-names></name>
<name><surname>Bae</surname><given-names>J.Y.</given-names></name>
<name><surname>Park</surname><given-names>M.S.</given-names></name>
<name><surname>Choi</surname><given-names>W.S.</given-names></name>
<name><surname>Park</surname><given-names>D.W.</given-names></name>
<name><surname>Noh</surname><given-names>J.Y.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>8016</fpage><lpage>8023</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.10.035</pub-id><pub-id pub-id-type="pmid">33131933</pub-id>
</element-citation></ref><ref id="B107-vaccines-13-00198"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Vaccines for hantaviruses: Progress and issues</article-title><source>Expert. Rev. Vaccines</source><year>2012</year><volume>11</volume><fpage>511</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1586/erv.12.15</pub-id><pub-id pub-id-type="pmid">22827236</pub-id>
</element-citation></ref><ref id="B108-vaccines-13-00198"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.Z.</given-names></name>
<name><surname>Zou</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>Z.F.</given-names></name>
<name><surname>Plyusnin</surname><given-names>A.</given-names></name>
</person-group><article-title>Hantavirus infections in humans and animals, China</article-title><source>Emerg. Infect. Dis.</source><year>2010</year><volume>16</volume><fpage>1195</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.3201/eid1608.090470</pub-id><pub-id pub-id-type="pmid">20678311</pub-id>
</element-citation></ref><ref id="B109-vaccines-13-00198"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>G.M.</given-names></name>
<name><surname>Han</surname><given-names>L.</given-names></name>
<name><surname>An</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>W.X.</given-names></name>
<name><surname>Kong</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>L.H.</given-names></name>
</person-group><article-title>Immunization effect of purified bivalent vaccine to haemorrhagic fever with renal syndrome manufactured from primary cultured hamster kidney cells</article-title><source>Chin. Med. J.</source><year>2005</year><volume>118</volume><fpage>766</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">15899141</pub-id>
</element-citation></ref><ref id="B110-vaccines-13-00198"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Y.Y.</given-names></name>
<name><surname>Xu</surname><given-names>Y.Q.</given-names></name>
<name><surname>Zhong</surname><given-names>Y.</given-names></name>
<name><surname>Wei</surname><given-names>F.</given-names></name>
<name><surname>Ling</surname><given-names>J.X.</given-names></name>
<name><surname>Li</surname><given-names>J.L.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Quan</surname><given-names>F.Y.</given-names></name>
<name><surname>Chen</surname><given-names>S.L.</given-names></name>
<name><surname>Luo</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>7482</fpage><lpage>7490</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.11.017</pub-id><pub-id pub-id-type="pmid">37953099</pub-id>
</element-citation></ref><ref id="B111-vaccines-13-00198"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Effects of nonlinear impulsive controls and seasonality on hantavirus infection</article-title><source>Math. Biosci.</source><year>2025</year><volume>380</volume><elocation-id>109378</elocation-id><pub-id pub-id-type="doi">10.1016/j.mbs.2025.109378</pub-id><pub-id pub-id-type="pmid">39828009</pub-id>
</element-citation></ref><ref id="B112-vaccines-13-00198"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vial</surname><given-names>P.A.</given-names></name>
<name><surname>Ferr&#x000e9;s</surname><given-names>M.</given-names></name>
<name><surname>Vial</surname><given-names>C.</given-names></name>
<name><surname>Klingstr&#x000f6;m</surname><given-names>J.</given-names></name>
<name><surname>Ahlm</surname><given-names>C.</given-names></name>
<name><surname>L&#x000f3;pez</surname><given-names>R.</given-names></name>
<name><surname>Le Corre</surname><given-names>N.</given-names></name>
<name><surname>Mertz</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Hantavirus in humans: A review of clinical aspects and management</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>e371</fpage><lpage>e382</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00128-7</pub-id><pub-id pub-id-type="pmid">37105214</pub-id>
</element-citation></ref><ref id="B113-vaccines-13-00198"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dzagurova</surname><given-names>T.K.</given-names></name>
<name><surname>Siniugina</surname><given-names>A.A.</given-names></name>
<name><surname>Ishmukhametov</surname><given-names>A.A.</given-names></name>
<name><surname>Egorova</surname><given-names>M.S.</given-names></name>
<name><surname>Kurashova</surname><given-names>S.S.</given-names></name>
<name><surname>Balovneva</surname><given-names>M.V.</given-names></name>
<name><surname>Deviatkin</surname><given-names>A.A.</given-names></name>
<name><surname>Tkachenko</surname><given-names>P.E.</given-names></name>
<name><surname>Leonovich</surname><given-names>O.A.</given-names></name>
<name><surname>Tkachenko</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Pre-Clinical Studies of Inactivated Polyvalent HFRS Vaccine</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>545372</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.545372</pub-id><pub-id pub-id-type="pmid">33251155</pub-id>
</element-citation></ref><ref id="B114-vaccines-13-00198"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurashova</surname><given-names>S.S.</given-names></name>
<name><surname>Ishmukhametov</surname><given-names>A.A.</given-names></name>
<name><surname>Dzagurova</surname><given-names>T.K.</given-names></name>
<name><surname>Egorova</surname><given-names>M.S.</given-names></name>
<name><surname>Balovneva</surname><given-names>M.V.</given-names></name>
<name><surname>Nikitin</surname><given-names>N.A.</given-names></name>
<name><surname>Evtushenko</surname><given-names>E.A.</given-names></name>
<name><surname>Karpova</surname><given-names>O.V.</given-names></name>
<name><surname>Markina</surname><given-names>A.A.</given-names></name>
<name><surname>Aparin</surname><given-names>P.G.</given-names></name>
<etal/>
</person-group><article-title>Various Adjuvants Effect on Immunogenicity of Puumala Virus Vaccine</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>545371</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2020.545371</pub-id><pub-id pub-id-type="pmid">33194793</pub-id>
</element-citation></ref><ref id="B115-vaccines-13-00198"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>P.Y.</given-names></name>
<name><surname>Wu</surname><given-names>X.A.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>Z.Y.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>L.F.</given-names></name>
<name><surname>Bai</surname><given-names>W.T.</given-names></name>
<name><surname>Zhang</surname><given-names>F.L.</given-names></name>
<etal/>
</person-group><article-title>Induction of Hantaan virus-specific immune responses in C57BL/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7</article-title><source>Int. J. Mol. Med.</source><year>2013</year><volume>32</volume><fpage>709</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1421</pub-id><pub-id pub-id-type="pmid">23783439</pub-id>
</element-citation></ref><ref id="B116-vaccines-13-00198"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>P.Y.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>X.A.</given-names></name>
<name><surname>Bai</surname><given-names>W.T.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>H.T.</given-names></name>
<name><surname>Hu</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>F.L.</given-names></name>
<name><surname>Xu</surname><given-names>Z.K.</given-names></name>
</person-group><article-title>Modification of the adenoviral transfer vector enhances expression of the Hantavirus fusion protein GnS0.7 and induces a strong immune response in C57BL/6 mice</article-title><source>J. Virol. Methods</source><year>2012</year><volume>179</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2011.10.005</pub-id><pub-id pub-id-type="pmid">22015676</pub-id>
</element-citation></ref><ref id="B117-vaccines-13-00198"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>L.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Ye</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Induction of specific humoral and cellular immune responses in a mouse model following gene fusion of HSP70C and Hantaan virus Gn and S0.7 in an adenoviral vector</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e88183</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0088183</pub-id><pub-id pub-id-type="pmid">24505421</pub-id>
</element-citation></ref><ref id="B118-vaccines-13-00198"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Safronetz</surname><given-names>D.</given-names></name>
<name><surname>Hegde</surname><given-names>N.R.</given-names></name>
<name><surname>Ebihara</surname><given-names>H.</given-names></name>
<name><surname>Denton</surname><given-names>M.</given-names></name>
<name><surname>Kobinger</surname><given-names>G.P.</given-names></name>
<name><surname>St Jeor</surname><given-names>S.</given-names></name>
<name><surname>Feldmann</surname><given-names>H.</given-names></name>
<name><surname>Johnson</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>7285</fpage><lpage>7295</lpage><pub-id pub-id-type="doi">10.1128/JVI.00373-09</pub-id><pub-id pub-id-type="pmid">19403663</pub-id>
</element-citation></ref><ref id="B119-vaccines-13-00198"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>K.S.</given-names></name>
<name><surname>Safronetz</surname><given-names>D.</given-names></name>
<name><surname>Marzi</surname><given-names>A.</given-names></name>
<name><surname>Ebihara</surname><given-names>H.</given-names></name>
<name><surname>Feldmann</surname><given-names>H.</given-names></name>
</person-group><article-title>Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>12781</fpage><lpage>12791</lpage><pub-id pub-id-type="doi">10.1128/JVI.00794-11</pub-id><pub-id pub-id-type="pmid">21917979</pub-id>
</element-citation></ref><ref id="B120-vaccines-13-00198"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prescott</surname><given-names>J.</given-names></name>
<name><surname>DeBuysscher</surname><given-names>B.L.</given-names></name>
<name><surname>Brown</surname><given-names>K.S.</given-names></name>
<name><surname>Feldmann</surname><given-names>H.</given-names></name>
</person-group><article-title>Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>516</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.3390/v6020516</pub-id><pub-id pub-id-type="pmid">24492621</pub-id>
</element-citation></ref><ref id="B121-vaccines-13-00198"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Warner</surname><given-names>B.M.</given-names></name>
<name><surname>Stein</surname><given-names>D.R.</given-names></name>
<name><surname>Jangra</surname><given-names>R.K.</given-names></name>
<name><surname>Slough</surname><given-names>M.M.</given-names></name>
<name><surname>Sroga</surname><given-names>P.</given-names></name>
<name><surname>Sloan</surname><given-names>A.</given-names></name>
<name><surname>Frost</surname><given-names>K.L.</given-names></name>
<name><surname>Booth</surname><given-names>S.</given-names></name>
<name><surname>Chandran</surname><given-names>K.</given-names></name>
<name><surname>Safronetz</surname><given-names>D.</given-names></name>
</person-group><article-title>Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>645</elocation-id><pub-id pub-id-type="doi">10.3390/v11070645</pub-id><pub-id pub-id-type="pmid">31337019</pub-id>
</element-citation></ref><ref id="B122-vaccines-13-00198"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Wei</surname><given-names>J.</given-names></name>
<name><surname>Dang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Ye</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Jin</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00814-2</pub-id><pub-id pub-id-type="pmid">38341504</pub-id>
</element-citation></ref><ref id="B123-vaccines-13-00198"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Peng</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Ye</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>A universal recombinant adenovirus type 5 vector-based COVID-19 vaccine</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1374486</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1374486</pub-id><pub-id pub-id-type="pmid">38745651</pub-id>
</element-citation></ref><ref id="B124-vaccines-13-00198"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zou</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>E.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
</person-group><article-title>Characterization of Pre-Existing Neutralizing Antibody to Human Adenovirus Types 5 and 49 and Simian Type 23 in Chinese Population</article-title><source>Viral Immunol.</source><year>2023</year><volume>36</volume><fpage>617</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1089/vim.2023.0023</pub-id><pub-id pub-id-type="pmid">37903228</pub-id>
</element-citation></ref><ref id="B125-vaccines-13-00198"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McClain</surname><given-names>D.J.</given-names></name>
<name><surname>Summers</surname><given-names>P.L.</given-names></name>
<name><surname>Harrison</surname><given-names>S.A.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>A.L.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine</article-title><source>J. Med. Virol.</source><year>2000</year><volume>60</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9071(200001)60:1&#x0003c;77::AID-JMV13&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">10568767</pub-id>
</element-citation></ref><ref id="B126-vaccines-13-00198"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>J.</given-names></name>
<name><surname>Ward</surname><given-names>S.</given-names></name>
<name><surname>Mendy</surname><given-names>J.</given-names></name>
<name><surname>Manayani</surname><given-names>D.J.</given-names></name>
<name><surname>Farness</surname><given-names>P.</given-names></name>
<name><surname>Avanzini</surname><given-names>J.B.</given-names></name>
<name><surname>Guenther</surname><given-names>B.</given-names></name>
<name><surname>Garduno</surname><given-names>F.</given-names></name>
<name><surname>Jow</surname><given-names>L.</given-names></name>
<name><surname>Snarsky</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e31177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031177</pub-id><pub-id pub-id-type="pmid">22363572</pub-id>
</element-citation></ref><ref id="B127-vaccines-13-00198"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>S.</given-names></name>
</person-group><article-title>Heterologous prime-boost vaccination</article-title><source>Curr. Opin. Immunol.</source><year>2009</year><volume>21</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.05.016</pub-id><pub-id pub-id-type="pmid">19500964</pub-id>
</element-citation></ref><ref id="B128-vaccines-13-00198"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suder</surname><given-names>E.</given-names></name>
<name><surname>Furuyama</surname><given-names>W.</given-names></name>
<name><surname>Feldmann</surname><given-names>H.</given-names></name>
<name><surname>Marzi</surname><given-names>A.</given-names></name>
<name><surname>de Wit</surname><given-names>E.</given-names></name>
</person-group><article-title>The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials</article-title><source>Hum. Vaccines Immunother.</source><year>2018</year><volume>14</volume><fpage>2107</fpage><lpage>2113</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1473698</pub-id><pub-id pub-id-type="pmid">29757706</pub-id>
</element-citation></ref><ref id="B129-vaccines-13-00198"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vrba</surname><given-names>S.M.</given-names></name>
<name><surname>Kirk</surname><given-names>N.M.</given-names></name>
<name><surname>Brisse</surname><given-names>M.E.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Ly</surname><given-names>H.</given-names></name>
</person-group><article-title>Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>680</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8040680</pub-id><pub-id pub-id-type="pmid">33202961</pub-id>
</element-citation></ref><ref id="B130-vaccines-13-00198"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monagle</surname><given-names>P.</given-names></name>
<name><surname>Ng</surname><given-names>A.P.</given-names></name>
<name><surname>Linden</surname><given-names>M.</given-names></name>
<name><surname>Ignjatovic</surname><given-names>V.</given-names></name>
<name><surname>Farley</surname><given-names>A.</given-names></name>
<name><surname>Taoudi</surname><given-names>S.</given-names></name>
<name><surname>Pasricha</surname><given-names>S.R.</given-names></name>
<name><surname>Torresi</surname><given-names>J.</given-names></name>
</person-group><article-title>Vaccine-induced immune thrombosis and thrombocytopenia syndrome following adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccination: A novel hypothesis regarding mechanisms and implications for future vaccine development</article-title><source>Immunol. Cell Biol.</source><year>2021</year><volume>99</volume><fpage>1006</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1111/imcb.12505</pub-id><pub-id pub-id-type="pmid">34664303</pub-id>
</element-citation></ref><ref id="B131-vaccines-13-00198"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yong</surname><given-names>C.Y.</given-names></name>
<name><surname>Ong</surname><given-names>H.K.</given-names></name>
<name><surname>Yeap</surname><given-names>S.K.</given-names></name>
<name><surname>Ho</surname><given-names>K.L.</given-names></name>
<name><surname>Tan</surname><given-names>W.S.</given-names></name>
</person-group><article-title>Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><elocation-id>1781</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.01781</pub-id><pub-id pub-id-type="pmid">31428074</pub-id>
</element-citation></ref><ref id="B132-vaccines-13-00198"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Michel</surname><given-names>M.L.</given-names></name>
<name><surname>Loirat</surname><given-names>D.</given-names></name>
</person-group><article-title>DNA vaccines for prophylactic or therapeutic immunization against hepatitis B</article-title><source>Intervirology</source><year>2001</year><volume>44</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1159/000050035</pub-id><pub-id pub-id-type="pmid">11509869</pub-id>
</element-citation></ref><ref id="B133-vaccines-13-00198"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goepfert</surname><given-names>P.A.</given-names></name>
<name><surname>Elizaga</surname><given-names>M.L.</given-names></name>
<name><surname>Seaton</surname><given-names>K.</given-names></name>
<name><surname>Tomaras</surname><given-names>G.D.</given-names></name>
<name><surname>Montefiori</surname><given-names>D.C.</given-names></name>
<name><surname>Sato</surname><given-names>A.</given-names></name>
<name><surname>Hural</surname><given-names>J.</given-names></name>
<name><surname>DeRosa</surname><given-names>S.C.</given-names></name>
<name><surname>Kalams</surname><given-names>S.A.</given-names></name>
<name><surname>McElrath</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>210</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu003</pub-id><pub-id pub-id-type="pmid">24403557</pub-id>
</element-citation></ref><ref id="B134-vaccines-13-00198"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stern</surname><given-names>P.L.</given-names></name>
</person-group><article-title>Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination</article-title><source>J. Clin. Virol.</source><year>2005</year><volume>32</volume><issue>(Suppl. S1)</issue><fpage>72</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2004.12.005</pub-id></element-citation></ref><ref id="B135-vaccines-13-00198"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geldmacher</surname><given-names>A.</given-names></name>
<name><surname>Skrastina</surname><given-names>D.</given-names></name>
<name><surname>Petrovskis</surname><given-names>I.</given-names></name>
<name><surname>Borisova</surname><given-names>G.</given-names></name>
<name><surname>Berriman</surname><given-names>J.A.</given-names></name>
<name><surname>Roseman</surname><given-names>A.M.</given-names></name>
<name><surname>Crowther</surname><given-names>R.A.</given-names></name>
<name><surname>Fischer</surname><given-names>J.</given-names></name>
<name><surname>Musema</surname><given-names>S.</given-names></name>
<name><surname>Gelderblom</surname><given-names>H.R.</given-names></name>
<etal/>
</person-group><article-title>An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice</article-title><source>Virology</source><year>2004</year><volume>323</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2004.02.022</pub-id><pub-id pub-id-type="pmid">15165823</pub-id>
</element-citation></ref><ref id="B136-vaccines-13-00198"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geldmacher</surname><given-names>A.</given-names></name>
<name><surname>Skrastina</surname><given-names>D.</given-names></name>
<name><surname>Borisova</surname><given-names>G.</given-names></name>
<name><surname>Petrovskis</surname><given-names>I.</given-names></name>
<name><surname>Kruger</surname><given-names>D.H.</given-names></name>
<name><surname>Pumpens</surname><given-names>P.</given-names></name>
<name><surname>Ulrich</surname><given-names>R.</given-names></name>
</person-group><article-title>A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3973</fpage><lpage>3983</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.02.025</pub-id><pub-id pub-id-type="pmid">15917119</pub-id>
</element-citation></ref><ref id="B137-vaccines-13-00198"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zvirbliene</surname><given-names>A.</given-names></name>
<name><surname>Kucinskaite-Kodze</surname><given-names>I.</given-names></name>
<name><surname>Razanskiene</surname><given-names>A.</given-names></name>
<name><surname>Petraityte-Burneikiene</surname><given-names>R.</given-names></name>
<name><surname>Klempa</surname><given-names>B.</given-names></name>
<name><surname>Ulrich</surname><given-names>R.G.</given-names></name>
<name><surname>Gedvilaite</surname><given-names>A.</given-names></name>
</person-group><article-title>The use of chimeric virus-like particles harbouring a segment of hantavirus Gc glycoprotein to generate a broadly-reactive hantavirus-specific monoclonal antibody</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>640</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.3390/v6020640</pub-id><pub-id pub-id-type="pmid">24513568</pub-id>
</element-citation></ref><ref id="B138-vaccines-13-00198"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Liang</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
</person-group><article-title>Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>4294</fpage><lpage>4300</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.025</pub-id><pub-id pub-id-type="pmid">20433802</pub-id>
</element-citation></ref><ref id="B139-vaccines-13-00198"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>T.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Ying</surname><given-names>Q.</given-names></name>
<name><surname>Han</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Yang</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection</article-title><source>J. Med. Microbiol.</source><year>2019</year><volume>68</volume><fpage>480</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000897</pub-id><pub-id pub-id-type="pmid">30657443</pub-id>
</element-citation></ref><ref id="B140-vaccines-13-00198"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fiedler</surname><given-names>J.D.</given-names></name>
<name><surname>Higginson</surname><given-names>C.</given-names></name>
<name><surname>Hovlid</surname><given-names>M.L.</given-names></name>
<name><surname>Kislukhin</surname><given-names>A.A.</given-names></name>
<name><surname>Castillejos</surname><given-names>A.</given-names></name>
<name><surname>Manzenrieder</surname><given-names>F.</given-names></name>
<name><surname>Campbell</surname><given-names>M.G.</given-names></name>
<name><surname>Voss</surname><given-names>N.R.</given-names></name>
<name><surname>Potter</surname><given-names>C.S.</given-names></name>
<name><surname>Carragher</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Engineered mutations change the structure and stability of a virus-like particle</article-title><source>Biomacromolecules</source><year>2012</year><volume>13</volume><fpage>2339</fpage><lpage>2348</lpage><pub-id pub-id-type="doi">10.1021/bm300590x</pub-id><pub-id pub-id-type="pmid">22830650</pub-id>
</element-citation></ref><ref id="B141-vaccines-13-00198"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Hao</surname><given-names>P.</given-names></name>
<name><surname>Jin</surname><given-names>X.</given-names></name>
</person-group><article-title>Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>6308</fpage><lpage>6320</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.063</pub-id><pub-id pub-id-type="pmid">28987441</pub-id>
</element-citation></ref><ref id="B142-vaccines-13-00198"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Jin</surname><given-names>X.</given-names></name>
</person-group><article-title>Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0194860</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0194860</pub-id><pub-id pub-id-type="pmid">29590178</pub-id>
</element-citation></ref><ref id="B143-vaccines-13-00198"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Dai</surname><given-names>W.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Leng</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Insect cell-produced recombinant protein subunit vaccines protect against Zika virus infection</article-title><source>Antivir. Res.</source><year>2018</year><volume>154</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2018.04.010</pub-id><pub-id pub-id-type="pmid">29665376</pub-id>
</element-citation></ref><ref id="B144-vaccines-13-00198"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antoniukas</surname><given-names>L.</given-names></name>
<name><surname>Grammel</surname><given-names>H.</given-names></name>
<name><surname>Reichl</surname><given-names>U.</given-names></name>
</person-group><article-title>Production of hantavirus Puumala nucleocapsid protein in Saccharomyces cerevisiae for vaccine and diagnostics</article-title><source>J. Biotechnol.</source><year>2006</year><volume>124</volume><fpage>347</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1016/j.jbiotec.2005.12.028</pub-id><pub-id pub-id-type="pmid">16513199</pub-id>
</element-citation></ref><ref id="B145-vaccines-13-00198"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klingstrom</surname><given-names>J.</given-names></name>
<name><surname>Maljkovic</surname><given-names>I.</given-names></name>
<name><surname>Zuber</surname><given-names>B.</given-names></name>
<name><surname>Rollman</surname><given-names>E.</given-names></name>
<name><surname>Kjerrstrom</surname><given-names>A.</given-names></name>
<name><surname>Lundkvist</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccination of C57/BL6 mice with Dobrava hantavirus nucleocapsid protein in Freund&#x02019;s adjuvant induced partial protection against challenge</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>4029</fpage><lpage>4034</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.045</pub-id><pub-id pub-id-type="pmid">15364453</pub-id>
</element-citation></ref><ref id="B146-vaccines-13-00198"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maes</surname><given-names>P.</given-names></name>
<name><surname>Keyaerts</surname><given-names>E.</given-names></name>
<name><surname>Bonnet</surname><given-names>V.</given-names></name>
<name><surname>Clement</surname><given-names>J.</given-names></name>
<name><surname>Avsic-Zupanc</surname><given-names>T.</given-names></name>
<name><surname>Robert</surname><given-names>A.</given-names></name>
<name><surname>Van Ranst</surname><given-names>M.</given-names></name>
</person-group><article-title>Truncated recombinant Dobrava hantavirus nucleocapsid proteins induce strong, long-lasting immune responses in mice</article-title><source>Intervirology</source><year>2006</year><volume>49</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1159/000093454</pub-id><pub-id pub-id-type="pmid">16714853</pub-id>
</element-citation></ref><ref id="B147-vaccines-13-00198"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maes</surname><given-names>P.</given-names></name>
<name><surname>Clement</surname><given-names>J.</given-names></name>
<name><surname>Cauwe</surname><given-names>B.</given-names></name>
<name><surname>Bonnet</surname><given-names>V.</given-names></name>
<name><surname>Keyaerts</surname><given-names>E.</given-names></name>
<name><surname>Robert</surname><given-names>A.</given-names></name>
<name><surname>Van Ranst</surname><given-names>M.</given-names></name>
</person-group><article-title>Truncated recombinant puumala virus nucleocapsid proteins protect mice against challenge in vivo</article-title><source>Viral Immunol.</source><year>2008</year><volume>21</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1089/vim.2007.0059</pub-id><pub-id pub-id-type="pmid">18355122</pub-id>
</element-citation></ref><ref id="B148-vaccines-13-00198"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>H.R.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>D.Y.</given-names></name>
<name><surname>Ling</surname><given-names>J.X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Y.J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Z.Q.</given-names></name>
</person-group><article-title>Specific humoral reaction of hemorrhagic fever with renal syndrome (HFRS) patients in China to recombinant nucleocapsid proteins from European hantaviruses</article-title><source>Eur. J. Clin. Microbiol. Infect. Dis.</source><year>2011</year><volume>30</volume><fpage>645</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1007/s10096-010-1134-5</pub-id><pub-id pub-id-type="pmid">21222012</pub-id>
</element-citation></ref><ref id="B149-vaccines-13-00198"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Abbasi</surname><given-names>S.W.</given-names></name>
<name><surname>Yousaf</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Muhammad</surname><given-names>K.</given-names></name>
<name><surname>Waheed</surname><given-names>Y.</given-names></name>
</person-group><article-title>Design of a Multi-Epitopes Vaccine against Hantaviruses: An Immunoinformatics and Molecular Modelling Approach</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>378</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10030378</pub-id><pub-id pub-id-type="pmid">35335010</pub-id>
</element-citation></ref><ref id="B150-vaccines-13-00198"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>H.L.</given-names></name>
<name><surname>McCluskie</surname><given-names>M.J.</given-names></name>
</person-group><article-title>DNA vaccines for viral diseases</article-title><source>Microbes Infect.</source><year>1999</year><volume>1</volume><fpage>7</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(99)80009-4</pub-id><pub-id pub-id-type="pmid">10594972</pub-id>
</element-citation></ref><ref id="B151-vaccines-13-00198"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
<name><surname>Spik</surname><given-names>K.W.</given-names></name>
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
</person-group><article-title>DNA vaccines for HFRS: Laboratory and clinical studies</article-title><source>Virus Res.</source><year>2014</year><volume>187</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2013.12.020</pub-id><pub-id pub-id-type="pmid">24370868</pub-id>
</element-citation></ref><ref id="B152-vaccines-13-00198"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
<name><surname>Custer</surname><given-names>D.M.</given-names></name>
<name><surname>Thompson</surname><given-names>E.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
</person-group><article-title>DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>8469</fpage><lpage>8477</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.18.8469-8477.2001</pub-id><pub-id pub-id-type="pmid">11507192</pub-id>
</element-citation></ref><ref id="B153-vaccines-13-00198"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
<name><surname>Kamrud</surname><given-names>K.I.</given-names></name>
<name><surname>Elgh</surname><given-names>F.</given-names></name>
<name><surname>Custer</surname><given-names>D.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
</person-group><article-title>DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection</article-title><source>Virology</source><year>1999</year><volume>255</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1006/viro.1998.9586</pub-id><pub-id pub-id-type="pmid">10069952</pub-id>
</element-citation></ref><ref id="B154-vaccines-13-00198"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boudreau</surname><given-names>E.F.</given-names></name>
<name><surname>Josleyn</surname><given-names>M.</given-names></name>
<name><surname>Ullman</surname><given-names>D.</given-names></name>
<name><surname>Fisher</surname><given-names>D.</given-names></name>
<name><surname>Dalrymple</surname><given-names>L.</given-names></name>
<name><surname>Sellers-Myers</surname><given-names>K.</given-names></name>
<name><surname>Loudon</surname><given-names>P.</given-names></name>
<name><surname>Rusnak</surname><given-names>J.</given-names></name>
<name><surname>Rivard</surname><given-names>R.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>1951</fpage><lpage>1958</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.01.024</pub-id><pub-id pub-id-type="pmid">22248821</pub-id>
</element-citation></ref><ref id="B155-vaccines-13-00198"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>J.</given-names></name>
<name><surname>Paolino</surname><given-names>K.M.</given-names></name>
<name><surname>Mills</surname><given-names>K.</given-names></name>
<name><surname>Kwilas</surname><given-names>S.</given-names></name>
<name><surname>Josleyn</surname><given-names>M.</given-names></name>
<name><surname>Cohen</surname><given-names>M.</given-names></name>
<name><surname>Somerville</surname><given-names>B.</given-names></name>
<name><surname>Wisniewski</surname><given-names>M.</given-names></name>
<name><surname>Norris</surname><given-names>S.</given-names></name>
<name><surname>Hill</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>377</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030377</pub-id><pub-id pub-id-type="pmid">32664486</pub-id>
</element-citation></ref><ref id="B156-vaccines-13-00198"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
<name><surname>Custer</surname><given-names>D.M.</given-names></name>
<name><surname>Smith</surname><given-names>J.</given-names></name>
<name><surname>Wahl-Jensen</surname><given-names>V.</given-names></name>
</person-group><article-title>Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates</article-title><source>Virology</source><year>2006</year><volume>347</volume><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.11.035</pub-id><pub-id pub-id-type="pmid">16378630</pub-id>
</element-citation></ref><ref id="B157-vaccines-13-00198"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
<name><surname>Ferro</surname><given-names>A.M.</given-names></name>
<name><surname>Wahl-Jensen</surname><given-names>V.</given-names></name>
</person-group><article-title>Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>1332</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1128/JVI.01822-07</pub-id><pub-id pub-id-type="pmid">18032485</pub-id>
</element-citation></ref><ref id="B158-vaccines-13-00198"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brocato</surname><given-names>R.L.</given-names></name>
<name><surname>Josleyn</surname><given-names>M.J.</given-names></name>
<name><surname>Wahl-Jensen</surname><given-names>V.</given-names></name>
<name><surname>Schmaljohn</surname><given-names>C.S.</given-names></name>
<name><surname>Hooper</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>218</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1128/CVI.00546-12</pub-id><pub-id pub-id-type="pmid">23239797</pub-id>
</element-citation></ref><ref id="B159-vaccines-13-00198"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Liang</surname><given-names>M.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>D.</given-names></name>
</person-group><article-title>Fusion with extracellular domain of cytotoxic T-lymphocyte-associated-antigen 4 leads to enhancement of immunogenicity of Hantaan virus DNA vaccines in C57BL/6 mice</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>448</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-448</pub-id><pub-id pub-id-type="pmid">21943202</pub-id>
</element-citation></ref><ref id="B160-vaccines-13-00198"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>D.B.</given-names></name>
<name><surname>Sun</surname><given-names>Y.J.</given-names></name>
<name><surname>Cheng</surname><given-names>L.F.</given-names></name>
<name><surname>Zhang</surname><given-names>G.F.</given-names></name>
<name><surname>Dong</surname><given-names>C.</given-names></name>
<name><surname>Jin</surname><given-names>B.Q.</given-names></name>
<name><surname>Song</surname><given-names>C.J.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>F.L.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
</person-group><article-title>Construction and evaluation of DNA vaccine encoding Hantavirus glycoprotein N-terminal fused with lysosome-associated membrane protein</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3367</fpage><lpage>3376</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.007</pub-id><pub-id pub-id-type="pmid">26027907</pub-id>
</element-citation></ref><ref id="B161-vaccines-13-00198"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>D.B.</given-names></name>
<name><surname>Zhang</surname><given-names>J.P.</given-names></name>
<name><surname>Cheng</surname><given-names>L.F.</given-names></name>
<name><surname>Zhang</surname><given-names>G.W.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Z.C.</given-names></name>
<name><surname>Lu</surname><given-names>Z.H.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.X.</given-names></name>
<name><surname>Lu</surname><given-names>Y.C.</given-names></name>
<name><surname>Zheng</surname><given-names>L.H.</given-names></name>
<etal/>
</person-group><article-title>Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy</article-title><source>Antivir. Res.</source><year>2018</year><volume>150</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.12.011</pub-id><pub-id pub-id-type="pmid">29273568</pub-id>
</element-citation></ref><ref id="B162-vaccines-13-00198"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>D.B.</given-names></name>
<name><surname>Sun</surname><given-names>L.J.</given-names></name>
<name><surname>Cheng</surname><given-names>L.F.</given-names></name>
<name><surname>Zhang</surname><given-names>J.P.</given-names></name>
<name><surname>Xiao</surname><given-names>S.B.</given-names></name>
<name><surname>Sun</surname><given-names>Y.J.</given-names></name>
<name><surname>Yang</surname><given-names>S.Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>F.L.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
</person-group><article-title>Recombinant DNA vaccine of Hantavirus Gn and LAMP1 induced long-term immune protection in mice</article-title><source>Antivir. Res.</source><year>2017</year><volume>138</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.12.001</pub-id><pub-id pub-id-type="pmid">27923570</pub-id>
</element-citation></ref><ref id="B163-vaccines-13-00198"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuzmin</surname><given-names>I.V.</given-names></name>
<name><surname>Soto Acosta</surname><given-names>R.</given-names></name>
<name><surname>Pruitt</surname><given-names>L.</given-names></name>
<name><surname>Wasdin</surname><given-names>P.T.</given-names></name>
<name><surname>Kedarinath</surname><given-names>K.</given-names></name>
<name><surname>Hernandez</surname><given-names>K.R.</given-names></name>
<name><surname>Gonzales</surname><given-names>K.A.</given-names></name>
<name><surname>Hill</surname><given-names>K.</given-names></name>
<name><surname>Weidner</surname><given-names>N.G.</given-names></name>
<name><surname>Mire</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>6421</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50774-3</pub-id><pub-id pub-id-type="pmid">39080316</pub-id>
</element-citation></ref><ref id="B164-vaccines-13-00198"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>D.</given-names></name>
<name><surname>Qiao</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus</article-title><source>NPJ Vaccines</source><year>2024</year><volume>9</volume><fpage>196</fpage><pub-id pub-id-type="doi">10.1038/s41541-024-00991-0</pub-id><pub-id pub-id-type="pmid">39443512</pub-id>
</element-citation></ref><ref id="B165-vaccines-13-00198"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ali</surname><given-names>L.</given-names></name>
<name><surname>Rauf</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Rasool</surname><given-names>S.</given-names></name>
<name><surname>Raza</surname><given-names>R.Z.</given-names></name>
<name><surname>Alshabrmi</surname><given-names>F.M.</given-names></name>
<name><surname>Khan</surname><given-names>T.</given-names></name>
<name><surname>Suleman</surname><given-names>M.</given-names></name>
<name><surname>Waheed</surname><given-names>Y.</given-names></name>
<name><surname>Mohammad</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>In silico design of multi-epitope vaccines against the hantaviruses by integrated structural vaccinology and molecular modeling approaches</article-title><source>PLoS ONE</source><year>2024</year><volume>19</volume><elocation-id>e0305417</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0305417</pub-id><pub-id pub-id-type="pmid">39042625</pub-id>
</element-citation></ref><ref id="B166-vaccines-13-00198"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhattacharya</surname><given-names>K.</given-names></name>
<name><surname>Chanu</surname><given-names>N.R.</given-names></name>
<name><surname>Jha</surname><given-names>S.K.</given-names></name>
<name><surname>Khanal</surname><given-names>P.</given-names></name>
<name><surname>Paudel</surname><given-names>K.R.</given-names></name>
</person-group><article-title>In silico design and evaluation of a multiepitope vaccine targeting the nucleoprotein of Puumala orthohantavirus</article-title><source>Proteins</source><year>2024</year><volume>92</volume><fpage>1161</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1002/prot.26703</pub-id><pub-id pub-id-type="pmid">38742930</pub-id>
</element-citation></ref><ref id="B167-vaccines-13-00198"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garry</surname><given-names>C.E.</given-names></name>
<name><surname>Garry</surname><given-names>R.F.</given-names></name>
</person-group><article-title>Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes)</article-title><source>Theor. Biol. Med. Model.</source><year>2004</year><volume>1</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/1742-4682-1-10</pub-id><pub-id pub-id-type="pmid">15544707</pub-id>
</element-citation></ref><ref id="B168-vaccines-13-00198"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noor</surname><given-names>F.</given-names></name>
<name><surname>Ashfaq</surname><given-names>U.A.</given-names></name>
<name><surname>Asif</surname><given-names>M.</given-names></name>
<name><surname>Adeel</surname><given-names>M.M.</given-names></name>
<name><surname>Alshammari</surname><given-names>A.</given-names></name>
<name><surname>Alharbi</surname><given-names>M.</given-names></name>
</person-group><article-title>Comprehensive computational analysis reveals YXXPhi[I/L/M/F/V] motif and YXXPhi-like tetrapeptides across HFRS causing Hantaviruses and their association with viral pathogenesis and host immune regulation</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1031608</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1031608</pub-id><pub-id pub-id-type="pmid">36275660</pub-id>
</element-citation></ref><ref id="B169-vaccines-13-00198"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noor</surname><given-names>F.</given-names></name>
<name><surname>Ashfaq</surname><given-names>U.A.</given-names></name>
<name><surname>Bakar</surname><given-names>A.</given-names></name>
<name><surname>Qasim</surname><given-names>M.</given-names></name>
<name><surname>Masoud</surname><given-names>M.S.</given-names></name>
<name><surname>Alshammari</surname><given-names>A.</given-names></name>
<name><surname>Alharbi</surname><given-names>M.</given-names></name>
<name><surname>Riaz</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Identification and characterization of codon usage pattern and influencing factors in HFRS-causing hantaviruses</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1131647</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1131647</pub-id><pub-id pub-id-type="pmid">37492567</pub-id>
</element-citation></ref><ref id="B170-vaccines-13-00198"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdulla</surname><given-names>F.</given-names></name>
<name><surname>Nain</surname><given-names>Z.</given-names></name>
<name><surname>Hossain</surname><given-names>M.M.</given-names></name>
<name><surname>Syed</surname><given-names>S.B.</given-names></name>
<name><surname>Ahmed Khan</surname><given-names>M.S.</given-names></name>
<name><surname>Adhikari</surname><given-names>U.K.</given-names></name>
</person-group><article-title>A comprehensive screening of the whole proteome of hantavirus and designing a multi-epitope subunit vaccine for cross-protection against hantavirus: Structural vaccinology and immunoinformatics study</article-title><source>Microb. Pathog.</source><year>2021</year><volume>150</volume><fpage>104705</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104705</pub-id><pub-id pub-id-type="pmid">33352214</pub-id>
</element-citation></ref><ref id="B171-vaccines-13-00198"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghafoor</surname><given-names>D.</given-names></name>
<name><surname>Kousar</surname><given-names>A.</given-names></name>
<name><surname>Ahmed</surname><given-names>W.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Ullah</surname><given-names>Z.</given-names></name>
<name><surname>Ullah</surname><given-names>N.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.</given-names></name>
<name><surname>Khan</surname><given-names>Z.</given-names></name>
<name><surname>Riaz</surname><given-names>R.</given-names></name>
</person-group><article-title>Computational vaccinology guided design of multi-epitopes subunit vaccine designing against Hantaan virus and its validation through immune simulations</article-title><source>Infect. Genet. Evol.</source><year>2021</year><volume>93</volume><fpage>104950</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.104950</pub-id><pub-id pub-id-type="pmid">34089911</pub-id>
</element-citation></ref><ref id="B172-vaccines-13-00198"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alabbas</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Integrativesubtractive proteomics, immunoinformatics, docking, and simulation approaches reveal candidate vaccine against Sin Nombre orthohantavirus</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1022159</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1022159</pub-id><pub-id pub-id-type="pmid">36439095</pub-id>
</element-citation></ref><ref id="B173-vaccines-13-00198"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almanaa</surname><given-names>T.N.</given-names></name>
<name><surname>Mubarak</surname><given-names>A.</given-names></name>
<name><surname>Sajjad</surname><given-names>M.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Hassan</surname><given-names>M.</given-names></name>
<name><surname>Waheed</surname><given-names>Y.</given-names></name>
<name><surname>Irfan</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
</person-group><article-title>Design and validation of a novel multi-epitopes vaccine against hantavirus</article-title><source>J. Biomol. Struct. Dyn.</source><year>2024</year><volume>42</volume><fpage>4185</fpage><lpage>4195</lpage><pub-id pub-id-type="doi">10.1080/07391102.2023.2219324</pub-id><pub-id pub-id-type="pmid">37261466</pub-id>
</element-citation></ref><ref id="B174-vaccines-13-00198"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>S.C.</given-names></name>
<name><surname>Li</surname><given-names>J.D.</given-names></name>
<name><surname>Lu</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Liu</surname><given-names>Q.Z.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.F.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>An</surname><given-names>Q.</given-names></name>
<name><surname>Liang</surname><given-names>M.F.</given-names></name>
<etal/>
</person-group><article-title>Hantavirus mucosal vaccine through different mucosal with heat-labile enterotoxin B subunit as adjuvants</article-title><source>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi</source><year>2008</year><volume>22</volume><fpage>174</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">19031694</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00198-f001"><label>Figure 1</label><caption><p>The worldwide distribution of orthohantavirus infection. Data published by PubMed and the International Travel Health Care Center (ITHCC). Sweden [<xref rid="B22-vaccines-13-00198" ref-type="bibr">22</xref>], China [<xref rid="B23-vaccines-13-00198" ref-type="bibr">23</xref>], North Korea/South Korea [<xref rid="B24-vaccines-13-00198" ref-type="bibr">24</xref>], Slovakia [<xref rid="B25-vaccines-13-00198" ref-type="bibr">25</xref>], Yugoslavia [<xref rid="B26-vaccines-13-00198" ref-type="bibr">26</xref>], Bulgaria [<xref rid="B27-vaccines-13-00198" ref-type="bibr">27</xref>], Slovenia [<xref rid="B28-vaccines-13-00198" ref-type="bibr">28</xref>], India [<xref rid="B29-vaccines-13-00198" ref-type="bibr">29</xref>], Norway [<xref rid="B29-vaccines-13-00198" ref-type="bibr">29</xref>], Finland [<xref rid="B30-vaccines-13-00198" ref-type="bibr">30</xref>], Romania [<xref rid="B31-vaccines-13-00198" ref-type="bibr">31</xref>], Japan [<xref rid="B32-vaccines-13-00198" ref-type="bibr">32</xref>], Belgium [<xref rid="B33-vaccines-13-00198" ref-type="bibr">33</xref>], Greece [<xref rid="B34-vaccines-13-00198" ref-type="bibr">34</xref>], Albania [<xref rid="B35-vaccines-13-00198" ref-type="bibr">35</xref>], Malaysia [<xref rid="B36-vaccines-13-00198" ref-type="bibr">36</xref>], Thailand [<xref rid="B37-vaccines-13-00198" ref-type="bibr">37</xref>], Central African Republic [<xref rid="B38-vaccines-13-00198" ref-type="bibr">38</xref>], France [<xref rid="B39-vaccines-13-00198" ref-type="bibr">39</xref>], Sri Lanka [<xref rid="B40-vaccines-13-00198" ref-type="bibr">40</xref>], Czech Republic [<xref rid="B41-vaccines-13-00198" ref-type="bibr">41</xref>], America [<xref rid="B24-vaccines-13-00198" ref-type="bibr">24</xref>], Brazil [<xref rid="B42-vaccines-13-00198" ref-type="bibr">42</xref>], Canada [<xref rid="B43-vaccines-13-00198" ref-type="bibr">43</xref>], Netherlands [<xref rid="B44-vaccines-13-00198" ref-type="bibr">44</xref>], Chile [<xref rid="B45-vaccines-13-00198" ref-type="bibr">45</xref>], Paraguay [<xref rid="B46-vaccines-13-00198" ref-type="bibr">46</xref>], Argentina [<xref rid="B47-vaccines-13-00198" ref-type="bibr">47</xref>], Singapore [<xref rid="B48-vaccines-13-00198" ref-type="bibr">48</xref>], Germany [<xref rid="B49-vaccines-13-00198" ref-type="bibr">49</xref>], Panama [<xref rid="B50-vaccines-13-00198" ref-type="bibr">50</xref>], Barbados [<xref rid="B51-vaccines-13-00198" ref-type="bibr">51</xref>], Indonesia [<xref rid="B52-vaccines-13-00198" ref-type="bibr">52</xref>], Luxembourg [<xref rid="B53-vaccines-13-00198" ref-type="bibr">53</xref>], Poland [<xref rid="B54-vaccines-13-00198" ref-type="bibr">54</xref>], French Guiana [<xref rid="B55-vaccines-13-00198" ref-type="bibr">55</xref>], Georgia [<xref rid="B56-vaccines-13-00198" ref-type="bibr">56</xref>], Switzerland [<xref rid="B57-vaccines-13-00198" ref-type="bibr">57</xref>], Turkey [<xref rid="B58-vaccines-13-00198" ref-type="bibr">58</xref>], Cuba [<xref rid="B59-vaccines-13-00198" ref-type="bibr">59</xref>], Iran [<xref rid="B60-vaccines-13-00198" ref-type="bibr">60</xref>], Colombia [<xref rid="B61-vaccines-13-00198" ref-type="bibr">61</xref>], Mozambique [<xref rid="B62-vaccines-13-00198" ref-type="bibr">62</xref>], Nepal [<xref rid="B63-vaccines-13-00198" ref-type="bibr">63</xref>], South Africa [<xref rid="B64-vaccines-13-00198" ref-type="bibr">64</xref>], Israel [<xref rid="B65-vaccines-13-00198" ref-type="bibr">65</xref>], Venezuela [<xref rid="B55-vaccines-13-00198" ref-type="bibr">55</xref>], Bolivia [<xref rid="B55-vaccines-13-00198" ref-type="bibr">55</xref>], Peru [<xref rid="B55-vaccines-13-00198" ref-type="bibr">55</xref>], Uruguay [<xref rid="B47-vaccines-13-00198" ref-type="bibr">47</xref>], Hungary [<xref rid="B66-vaccines-13-00198" ref-type="bibr">66</xref>].</p></caption><graphic xlink:href="vaccines-13-00198-g001" position="float"/></fig><fig position="float" id="vaccines-13-00198-f002"><label>Figure 2</label><caption><p>Schematic representation of the orthohantavirus virion. The orthohantavirus particle contains the viral RNA (vRNA) genome, which comprises small, medium, and large ORFs. These are encapsidated by the nucleocapsid protein. The outer part of the virion glycoprotein is composed of Gn and Gc. The viral genome is replicated and transcribed by RNA polymerase. The diameter of the virus is approximately 80&#x02013;120 nm.</p></caption><graphic xlink:href="vaccines-13-00198-g002" position="float"/></fig><fig position="float" id="vaccines-13-00198-f003"><label>Figure 3</label><caption><p>Temporal dynamics of orthohantavirus-specific immunoglobulins during the onset of HFRS. This figure references previously published Chinese literature and one review [<xref rid="B91-vaccines-13-00198" ref-type="bibr">91</xref>].</p></caption><graphic xlink:href="vaccines-13-00198-g003" position="float"/></fig><table-wrap position="float" id="vaccines-13-00198-t001"><object-id pub-id-type="pii">vaccines-13-00198-t001_Table 1</object-id><label>Table 1</label><caption><p>Existing DNA vaccines in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">NCT Number</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Title</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Type</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Funder</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Number Enrolled</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Date</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Status</th><th align="center" valign="middle" style="border-top:solid thin; border-bottom:solid thin" rowspan="1" colspan="1">Major Outcomes</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">02776761</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hantaan vaccine, Puumala vaccine, mixed Hantaan/Puumala vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I: single-center, randomized, single-blinded</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. Army Medical Research and Development Command</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 August 2016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralizing antibody responses: 7/7 (100%) of HTNV vaccines; 6/6 (100%) of PUUV vaccines; 4/9 (44%) seroconversion against both viruses of mixed vaccines</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">02116205</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hantaan/Puumala vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase IIa: randomized, double-blind, dose-optimizing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. Army Medical Research and Development Command</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">130</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 July 2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">04333459</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For the Prevention of Hemorrhagic Fever With Renal Syndrome</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hantaan Vaccine/Puumala Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase II: randomized, double-blind</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. Army Medical Research and Development Command</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 August 2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">03682107</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Andes virus vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I:<break/>randomized, placebo controlled, double-blind, dose escalation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">National Institute of Allergy and Infectious Diseases</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 February 2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98% and 65% of subjects had at least 1 local or systemic solicited adverse event</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">03718130</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Combination HTNV and PUUV DNA Vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine&#x02013;device combination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I: randomized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. Army Medical Research and Development Command</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 October 2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">01502345</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine&#x02013;device combination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I: randomized</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U.S. Army Medical Research and Development Command</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18&#x02013;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">January 2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complete</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></floats-group></article>